WO2015177674A1

WO2015177674A1 - Gene cluster for biosynthesis of cornexistin and hydroxycornexistin

Info

Publication number: WO2015177674A1
Application number: PCT/IB2015/053442
Authority: WO
Inventors: Oskar Zelder; Birgit HOFF; Hartwig Schröder; Andrea MOLT; Holger Hartmann; Florian Vogt
Original assignee: Basf Se; Basf (China) Company Limited
Priority date: 2014-05-21
Filing date: 2015-05-11
Publication date: 2015-11-26
Also published as: KR20170002658A; JP2017515494A

Abstract

Provided are polynucleotides encoding polypeptides involved in the biosynthesis of cornexistin and hydroxycornexistin as well as vectors and recombinant microorganisms comprising the polynucleotides. Also provided are methods for the production of natural products, in particular methods for the production of cornexistin and hydroxycornexistin, using said polynucleotides and polypeptides encoded therein, as well as vectors and recombinant microorganisms comprising said polynucleotides and polypeptides.

Description

GENE CLUSTER FOR BIOSYNTHESIS OF CORNEXISTIN AND

HYDROXYCORNEXISTIN

This application claims priority of applications with number EP 14169323.4 and

EP14169318.4, all of which are incorporated by reference in their entirety.

FIELD OF THE INVENTION

The invention pertains to the field of production of natural products and, in particular, in the field of production of cornexistin and hydroxycornexistin. It provides polynucleotides encoding polypeptides involved in the biosynthesis of cornexistin and hydroxycornexistin as well as vectors and recombinant microorganisms comprising such polynucleotides. Also provided are methods for the production of natural products, in particular methods for the production of cornexistin and hydroxycornexistin, using such polynucleotides and

polpeptides encoded therein, as well as vectors and recombinant microorganisms comprising such polynucleotides and polypeptides.

BACKGROUND OF THE INVENTION

Cornexistin and hydroxycornexistin are natural products derived from the fungus

Paecilomyces divaricatus formerly known as Paecilomyces variotii SANK 21086. Both, cornexistin and hydroxycornexistin, are highly potent herbicides that have the unique quality of being harmless to corn plants. Because of this quality, both molecules have attracted research interest. The Sankyo Corporation discovered cornexistin during the screening of biological extracts for herbicidal use (JP2256602). Cornexistin showed good activity as a herbicide as well as relative inactivity towards corn plants. Sankyo' s characterization showed this fungal natural product to be a member of the nonadride family, a group of natural products known for their interesting structural characteristics including a central nine-membered ring, fused maleic anhydrides and pendant alkyl chains. Cornexistin and hydroxycornexistin has been synthesized by chemical synthesis only as diastereomeres (Org. Biomol. Chem., 2008, 6, 4012- 4025). Nine-membered carbocyclic structures in general are rare in nature and their synthesis as well as the genes involved in the synthesis are still unknown and not described.

Isolation of cornexistin from the cultures of Paecilomyces species originally identified as Paecilomyces variotii SANK 21086 was published as early as 1989 by the Sankyo research group JP2256602). Later work from the DOW Elanco group described identification of hydroxycornexistin also produced in Paecilomyces variotii SANK 21086 (US00542478). However, the yield of the producing strain SANK 21086 under fermentation conditions is believed to be too low for commercial production purposes.

Genes involved in the production of cornexistin and hydroxycornexistin have recently been isolated from filamentus fungi of the species Paecilomyces divaricatus (US 14/084030 and EP13182735.4). Further genes, which support the production of cornexistin and hydroxycornexistin have been found in the species Talaromyces stipitatus and Bipolaris maydis. Bipolaris maydis is also known as Cochliobolus heterostrophus, Drechslera maydis, Helminthosporium maydis and Ophiobolus heterostrophus. These genes of Talaromyces stipitatus and Bipolaris maydis and variants thereof as well as their applications are described below.

The technical problem underlying the present invention can be seen as the provision of additional means and methods for the production of cornexistin or hydroxycornexistin, or both. The technical problem is solved by the embodiments characterized in the claims and herein below.

SUMMARY OF THE INVENTION

The present invention provides polynucleotides of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH being involved in the production of cornexistin, and/or

hydroxycornexistin which can be isolated from Talaromyces stipitatus or Bipolaris maydis. The invention provides also variants of these polynucleotides and recombinant

microorganisms comprising such polynucleotides. Such recombinant microorganisms may be used for the production of cornexistin, or hydroxycornexistin, or both as well as for the production of precursors of cornexistin and hydroxycornexistin. The polynucleotides are preferably comprised by expression cassettes which enable the recombinant microorganism to express the encoded polypeptides and to provide the recombinant microorganism with the function of at least one of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, or to provide the recombinant microorganism with an additional gene for the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, in case the microorganism has already an endogenous gene for the respective function of geneA, geneB, geneC, geneD, geneE, geneF, geneG, or geneH.

Preferably, the microorganism used as a host for the described polypnucleotides and polypeptides is already capable to produce cornexistin or hydroxycornexistin, or both. Such a microorganism may be transformed to enhance the capacity for production of cornexistin, or hydroxycornexistin, or both, due to at least one additional copy of geneA, geneB, geneC, geneD, geneE, geneF, geneG, or geneH. In some embodiments the microorganism is transformed to complement a missing gene function in order to provide the microorganism with the capacity to produce cornexistin, or hydroxycornexistin, or both. In some

embodiments, the microorganism is transformed in order to destroy or to downregulate its capacity to produce cornexistin, or hydroxycornexistin, or both. The recombinant

microorganism is preferably selected from the group of filamentous fungi, in particular from the genus Aspergillus, Penicillium, Paecilomyces or Talaromyces. Preferably, the

recombinant microorganism is capable to produce cornexistin or hydroxycornexistin or both. A particular preferred microorganism is Paecillomyces divaricatus. Preferably the

recombinant microorganisms comprise also polynucleotides isolated from Paecilomyces divaricatus and variants thereof encoding polypeptides for at least one function of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, geneR. Preferably for at least two, three, four, five, six, seven, eight, nine or all of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, geneR.

The invention provides also for recombinant microorganisms, which comprise the entire metabolic pathway for the production of cornexistin or hydroxycornestin or at least one of their precursors, wherein at least one of the polynucleotides for the functions of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, can be isolated from Talaromyces stipitatus or is a variant of such a polynucleotide, and a wherein at least one of the polynucleotides for the functions of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH can be isolated from Bipolaris maydis, or is a variant of such a polynucleotide. These recombinant microorganisms preferably comprise at least one polynucleotide for the fuction of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ or geneR, which could be isolated from Paecillomyces divaricatus, or is a variant of such a

polynucleotide. Preferably the recombinant microorganisms comprise combinations of expression cassettes for several gene functions. For example, but not excluding other combinations, comprising expression cassettes for at least the functions of geneK and geneL, or geneN and geneP, or geneK and geneQ, or comprising expression cassettes for at least the functions of geneK, geneL, geneN, geneP, and geneQ, or comprising expression cassettes for at least the functions of of genel, geneJ, geneK, geneL, geneN, geneP, and geneQ, or comprising expression cassettes for at least the functions of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ and geneR, wherein at least one of the expression cassettes is a recombinant expression cassette, or wherein at least one of the expression cassettes is comprised by a recombinant polynucleotide.

As the recombinant microorganism provided by the invention can be used in methods and processes for the production of cornexistin, hycroxycornexistin or both, the invention comprises also methods and processes for the production of of cornexistin,

hycroxycornexistin or both as well as the use of the recombinant microorganism in such methods and processes.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1a to Figure 1 m (together Figure 1) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 2) encoded by geneA and exemplary variants thereof (SEQ ID NO: 4, 6, 8, 10 and 12). SEQ ID NO: 14 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code.

A similar alignment of SEQ ID NO: 244, exemplary variants thereof (SEQ ID NO: 245, 246, 247, 248, 249, 250, 251 , 252, 253 and 254) and SEQ ID NO: 14 can readily prepared and is shown in Figure 1 of EP14169323.4, which is included herein by reference. Further sequence variants SEQ ID NO: 2 and SEQ ID NO: 244 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background.

Amino acid positions marked with a black arrow are the same in Figure 1 and in Figure 1 of EP 14169323.4 in reference to SEQ ID NO: 14. Figure 2a and Figure 2b (together Figure 2) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 21 ) encoded by geneB and exemplary variants thereof (SEQ ID NO: 23, 25, 27, 29 and 31 ). SEQ ID NO: 33 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code. A similar alignment of SEQ ID NO: 256, exemplary variants thereof (SEQ ID NO: 257, 258, 259, 260, 261 , 262, 263, 264, 265 and 266) and SEQ ID NO: 14 and a similar alignment of SEQ ID NO: 340, exemplary variants thereof (SEQ ID NO: 341 , 342, 343, 344, 345, 346, 347, 348, 349 and 350) and SEQ ID NO: 33 can readily prepared and are shown in Figure 2 and Figure 9 of EP 14169323.4, both of which are included herein by reference. Further sequence variants of SEQ ID NO: 21 , SEQ ID NO: 256 and SEQ ID NO: 340 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 2 and in Figure 2 and Figure 9 of EP14169323.4 in reference to SEQ ID NO: 33.

Figures 3a to Figure 3c (together Figure 3) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 40) encoded by geneC and exemplary variants thereof (SEQ ID NO: 42, 44, 46, 48 and 50). SEQ ID NO: 52 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code. A similar alignment of SEQ ID NO: 268, exemplary variants thereof (SEQ ID NO: 269, 270, 271 , 272, 273, 274, 275, 276, 277 and 278) and SEQ ID NO: 52 can readily prepared and is shown in Figure 3 of EP 14169323.4, which is included herein by reference. Further sequence variants SEQ ID NO: 40 and SEQ ID NO: 268 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 3 and in Figure 3 of EP14169323.4 in reference to SEQ ID NO: 52.

Figures 4a to Figure 4c (together Figure 4) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 59) encoded by geneD and exemplary variants thereof (SEQ ID NO: 61 , 63, 65, 67 and 69). SEQ ID NO: 71 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code. A similar alignment of SEQ ID NO: 280, exemplary variants thereof (SEQ ID NO: 281 , 282, 283, 284, 285, 286, 287, 288, 289 and 290) and SEQ ID NO: 71 can readily prepared and is shown in Figure 4 of EP14169323.4, which is included herein by reference. Further sequence variants SEQ ID NO: 59 and SEQ ID NO: 280 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 4 and in Figure 4 of EP14169323.4 in reference to SEQ ID NO: 71.

Figure 5a and Figure 5b (together Figure 5) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 78) encoded by geneE and variants thereof (SEQ ID NO: 80, 82, 84, 86 and 88). SEQ ID NO: 90 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code.

A similar alignment of SEQ ID NO: 292, exemplary variants thereof (SEQ ID NO: 293, 294, 295, 296, 297, 298, 299, 300, 301 and 302) and SEQ ID NO: 78 can readily prepared and is shown in Figure 5 of EP14169323.4, which is included herein by reference. Further sequence variants SEQ ID NO: 78 and SEQ ID NO: 292 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 5 and in Figure 5 of EP14169323.4 in reference to SEQ ID NO: 78.

Figure 6a and Figure 6b (together Figure 6) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 97) encoded by geneF and variants thereof (SEQ ID NO: 99, 101 , 103, 105 and 107). SEQ ID NO: 109 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. A similar alignment of SEQ ID NO: 304, exemplary variants thereof (SEQ ID NO: 305, 306, 307, 308, 309, 310, 31 1 , 312, 313 and 314) and SEQ ID NO: 109 can readily prepared and is shown in Figure 6 of EP14169323.4, which is included herein by reference. The amino acids are represented according to the standard single letter amino acid code. Further sequence variants SEQ ID NO: 97 and SEQ ID NO: 304 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 6 and in Figure 6 of EP14169323.4 in reference to SEQ ID NO: 109.

Figures 7a to Figure 7c (together Figure 7) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 1 16) encoded by geneG and variants thereof (SEQ ID NO: 1 18, 120, 122, 124 and 126). SEQ ID NO: 128 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code. A similar alignment of SEQ ID NO: 316, exemplary variants thereof (SEQ ID NO: 317, 318, 319, 320, 321 , 322, 323, 324, 325 and 326) and SEQ ID NO: 128 can readily prepared and is shown in Figure 7 of EP14169323.4, which is included herein by reference. Further sequence variants SEQ ID NO: 1 16 and SEQ ID NO: 316 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 7 and in Figure 7 of EP14169323.4 in reference to SEQ ID NO: 128.

Figures 8a to Figure 8c (together Figure 8) represent consecutive parts of an amino acid sequence alignment of the polypeptide (SEQ ID NO: 135) encoded by geneH and variants thereof (SEQ ID NO: 137, 139, 141 , 143 and 145). SEQ ID NO: 147 represents an amino acid sequence of a gene from Paecilomyces divaricatus which provides a similar activity. The amino acids are represented according to the standard single letter amino acid code. A similar alignment of SEQ ID NO: 328, exemplary variants thereof (SEQ ID NO: 329, 330, 331 , 332, 333, 334, 335, 336, 337 and 338) and SEQ ID NO: 147 can readily prepared and is shown in Figure 8 of EP14169323.4, which is included herein by reference. Further sequence variants SEQ ID NO: 135 and SEQ ID NO: 328 can be deduced from these alignments. Such sequence variants preferably have no change in the amino acids marked with a black arrow. More preferred, the variants will only have conservative amino acid substitutions in the amino acids depicted as white letters on a black background. Amino acid positions marked with a black arrow are the same in Figure 8 and in Figure 8 of EP14169323.4 in reference to SEQ ID NO: 147.

GENENERAL DEFINITIONS

The term " cornexistin" means a compound of Formula (I)

Formula (I) The term " dibasic acid of cornexistin" means a compound of Formula (II) as well as salts of this compound, in particular agriculturally acceptable salts of a compound of Formula (II).

Formula (II)

The term " hydroxycornexistin" means a compound of Formula (III).

Formula (III)

The term " dibasic acid of hydroxycornexistin" means a compound of Formula (IV) as well as salts of this compound, in particular agriculturally acceptable salts of a compound of Formula (IV).

Formula (IV)

The compounds of Formulas I to IV as described herein are capable of forming geometrical isomers, for example E/Z isomers. They possess also several centers of chirality and, as a consequence, van be present as enantiomers or diastereomers. The compounds of

Formulas II and IV are capable to form salts. Accordingly, the terms " cornexistin"

" dibasic acid of cornexistin" , " hydroxycornexistin" and " dibasic acid of hydroxycornexistin" , in a broad sense, will also encompass the isomers and mixtures thereof as well as the pure enantiomers and diastereomers and their mixtures, as well as the salts of compounds of the Formula I to IV, preferably agriculturally acceptable salts of compounds of the Formula I to IV, more preferred agriculturally acceptable salts of compounds of the Formula II and IV.

In a strict interpretation of the terms " cornexistin" " dibasic acid of cornexistin" ,

" hydroxycornexistin" and " dibasic acid of hydroxycornexistin" these terms will mean compounds as described by the respective Formula I to IV and their agriculturally acceptable salts

The term " agriculturally acceptable salts" is used herein to mean in general, the salts of those cations and the acid addition salts of those acids whose cations and anions, respectively, have no adverse effect on the herbicidal activity of the dibasic acid of cornexistin, the dibasic acid of hydroxycornexistin and preferably have no adverse effect on the herbicidal activity of the dibasic acid of cornexistin and the dibasic acid of

hydroxycornexistin.

Preferred cations are the ions of the alkali metals, preferably of lithium, sodium and potassium, of the alkaline earth metals, preferably of calcium and magnesium, and of the transition metals, preferably of manganese, copper, zinc and iron, further ammonium and substituted ammonium in which one to four hydrogen atoms are replaced by C1 -C4-alkyl, hydroxy-C1 -C4-alkyl, C1 -C4-alkoxy-C1 -C4-alkyl, hydroxy-C1 -C4-alkoxy-C1 -C4-alkyl, phenyl or benzyl, preferably ammonium, methylammonium, isopropylammonium, dimethylammonium, diisopropylammonium, trimethylammonium, heptylammonium, dodecylammonium, tetradecylammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, 2 hydroxyethyl-ammonium (olamine salt), 2-(2-hydroxyeth-1 -oxy)eth- 1 -ylammonium (diglycolamine salt), di(2-hydroxyeth-1 -yl)-ammonium (diolamine salt), tris(2- hydroxyethyl)ammonium (trolamine salt), tris(2-hydroxypropyl)ammonium,

benzyltrimethylammonium, benzyltriethylammonium, Ν,Ν,Ν-trimethylethanolammonium (choline salt), furthermore phosphonium ions, sulfonium ions, preferably tri(C1 -C4- alkyl)sulfonium, such as trimethylsulfonium, and sulfoxonium ions, preferably tri(C1 -C4- alkyl)sulfoxonium, and finally the salts of polybasic amines such as N,N-bis-(3- aminopropyl)methylamine and diethylenetriamine. Anions of useful acid addition salts are primarily chloride, bromide, fluoride, iodide, hydrogensulfate, methylsulfate, sulfate, dihydrogenphosphate, hydrogen phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate and also the anions of C1 -C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. The term " about" is used herein to mean approximately, roughly, around, or in the region of. When the term " about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values-set forth. In general, the term " about" is used herein to modify a numerical value above and below the stated value by a variance of 20 percent up or down (higher or lower), preferably 15 percent, more preferably 10 percent and most preferably 5 percent. The term "genome" or "genomic DNA" is referring to the heritable genetic information of a host organism. Said genomic DNA comprises the entire genetic material of a cell or an organism, including the DNA of the nucleus (chromosomal DNA), extrachromosomal DNA, and organellar DNA (e.g. of mitochondria). Preferably, the terms genome or genomic DNA is referring to the chromosomal DNA of the nucleus.

The term "chromosomal DNA" or "chromosomal DNA sequence" is to be understood as the genomic DNA of the cellular nucleus independent from the cell cycle status. Chromosomal DNA might therefore be organized in chromosomes or chromatids, they might be condensed or uncoiled. An insertion into the chromosomal DNA can be demonstrated and analyzed by various methods known in the art like e.g., polymerase chain reaction (PCR) analysis, Southern blot analysis, fluorescence in situ hybridization (FISH), in situ PCR and next generation sequencing (NGS).

The term " promoter" refers to a polynucleotide which directs the transcription of a structural gene to produce mRNA. Typically, a promoter is located in the 5' region of a gene, proximal to the start codon of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent, if the promoter is a constitutive promoter.

The term " enhancer" refers to a polynucleotide. An enhancer can increase the efficiency with which a particular gene is transcribed into mRNA irrespective of the distance or orientation of the enhancer relative to the start site of transcription. Usually an enhancer is located close to a promoter, a 5' -untranslated sequence or in an intron.

A polynucleotide is "heterologous to" an organism or a second polynucleotide if it originates from a foreign species, or, if from the same species, is modified from its original form. For example, a promoter operably linked to a heterologous coding sequence refers to a coding sequence from a species different from that from which the promoter was derived, or, if from the same species, a coding sequence which is not naturally associated with the promoter (e. g. a genetically engineered coding sequence or an allele from a different ecotype or variety).

"Transgene", " transgenic" or "recombinant" refers to a polynucleotide manipulated by man or a copy or complement of a polynucleotide manipulated by man. For instance, a transgenic expression cassette comprising a promoter operably linked to a second polynucleotide may include a promoter that is heterologous to the second polynucleotide as the result of manipulation by man (e.g., by methods described in Sambrook et al., Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989) or Current Protocols in Molecular Biology Volumes 1 -3, John Wiley & Sons, Inc. (1994-1998)) of an isolated nucleic acid comprising the expression cassette. In another example, a recombinant expression cassette may comprise polynucleotides combined in such a way that the polynucleotides are extremely unlikely to be found in nature. For instance, restriction sites or plasmid vector sequences manipulated by man may flank or separate the promoter from the second polynucleotide. One of skill will recognize that polynucleotides can be manipulated in many ways and are not limited to the examples above.

In case the term "recombinant" is used to specify an organism or cell, e.g. a microorganism, it is used to express that the organism or cell comprises at least one "transgene",

" transgenic" or "recombinant" polynucleotide, which is usually specified later on. A polynucleotide "exogenous to" an individual organism is a polynucleotide which is introduced into the organism by any means other than by a sexual cross.

The terms " operable linkage" or " operably linked" are generally understood as meaning an arrangement in which a genetic control sequence, e.g. a promoter, enhancer or terminator, is capable of exerting its function with regard to a polynucletide being operably linked to it, for example a polynucleotide encoding a polypeptide. Function, in this context, may mean for example control of the expression, i.e. transcription and/or translation, of the nucleic acid sequence. Control, in this context, encompasses for example initiating, increasing, governing or suppressing the expression, i.e. transcription and, if appropriate, translation. Controlling, in turn, may be, for example, tissue- and / or time-specific. It may also be inducible, for example by certain chemicals, stress, pathogens and the like.

Preferably, operable linkage is understood as meaning for example the sequential arrangement of a promoter, of the nucleic acid sequence to be expressed and, if

appropriate, further regulatory elements such as, for example, a terminator, in such a way that each of the regulatory elements can fulfill its function when the nucleic acid sequence is expressed. An operably linkage does not necessarily require a direct linkage in the chemical sense. Genetic control sequences such as, for example, enhancer sequences are also capable of exerting their function on the target sequence from positions located at a distance to the polynucleotide, which is operably linked. Preferred arrangements are those in which the nucleic acid sequence to be expressed is positioned after a sequence acting as promoter so that the two sequences are linked covalently to one another. The distance between the promoter and the amino acid sequence encoding polynucleotide in an expression cassette, is preferably less than 200 base pairs, especially preferably less than 100 base pairs, very especially preferably less than 50 base pairs. The skilled worker is familiar with a variety of ways in order to obtain such an expression cassette. However, an expression cassette may also be constructed in such a way that the nucleic acid sequence to be expressed is brought under the control of an endogenous genetic control element, for example an endogenous promoter, for example by means of homologous recombination or else by random insertion. Such constructs are likewise understood as being expression cassettes for the purposes of the invention. The term " expression cassette" means those construct in which the nucleic acid sequence encoding an amino acid sequence to be expressed is linked operably to at least one genetic control element which enables or regulates its expression (i.e. transcription and / or translation). The expression may be, for example, stable or transient, constitutive or inducible.

The terms " express," " expressing," " expressed" and " expression" refer to expression of a gene product (e.g., a biosynthetic enzyme of a gene of a pathway or reaction defined and described in this application) at a level that the resulting enzyme activity of this protein encoded for, or the pathway or reaction that it refers to allows metabolic flux through this pathway or reaction in the organism in which this gene/pathway is expressed in. The expression can be done by genetic alteration of the microorganism that is used as a starting organism. In some embodiments, a microorganism can be genetically altered (e.g., genetically engineered) to express a gene product at an increased level relative to that produced by the starting microorganism or in a comparable microorganism which has not been altered. Genetic alteration includes, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g. by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site or transcription terminator, increasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene using routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins).

In some embodiments, a microorganism can be physically or environmentally altered to express a gene product at an increased or lower level relative to level of expression of the gene product unaltered microorganism. For example, a microorganism can be treated with, or cultured in the presence of an agent known, or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

The terms " deregulate," " deregulated" and " deregulation" refer to alteration or modification of at least one gene in a microorganism, wherein the alteration or modification results in increasing efficiency of production of a given compound in the microorganism relative to production in absence of the alteration or modification. In some embodiments, a gene that is altered or modified encodes an enzyme in a biosynthetic pathway, or a transport protein, such that the level or activity of the biosynthetic enzyme in the

microorganism is altered or modified, or that the transport specificity or efficiency is altered or modified. In some embodiments, at least one gene that encodes an enzyme in a biosynthetic pathway, i.e. a polypeptide bringing about a specific activity in the biosynthetic pathway, is altered or modified such that the level or activity of the enzyme is enhanced or increased relative to the level in presence of the unaltered or wild type gene.

Deregulation also includes altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity. Also, deregulation further encompasses genetic alteration of genes encoding transcriptional factors (e.g., activators, repressors) which regulate expression of genes coding for enzymes or transport proteins. The terms " deregulate," " deregulated" and " deregulation" can further be specified in regard to the kind of deregulation present.

In case the particular activity, is altered or modified such that the level or activity of the enzyme is enhanced or increased relative to the level in presence of the unaltered or wild type gene, the term " up-regulated" is used. In case particular activity, is altered or modified such that the level or activity of the enzyme is lowered or decreased relative to the level in presence of the unaltered or wild type gene, the term " down -regulated" is used.

The term " deregulated" includes expression of a gene product at a level lower or higher than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically manipulated (e.g., genetically engineered) to express a level of gene product at a lesser or higher level than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. Genetic manipulation can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g., by removing strong promoters, inducible promoters or multiple promoters), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site or transcription terminator, decreasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, or other methods to knock-out or block expression of the target protein).

The term " deregulated gene activity" also means that a gene activity is introduced into a microorganism where the respective gene activity, has not been observed before, e.g. by introducing a recombinant gene, e.g. a heterologous gene, in one or more copies into the microorganism preferably by means of genetic engineering. The phrase " deregulated pathway or reaction" refers to a biosynthetic pathway or reaction in which at least one gene that encodes an enzyme in a biosynthetic pathway or reaction is altered or modified such that the level or activity of at least one biosynthetic enzyme is altered or modified. The phrase " deregulated pathway" includes a

biosynthetic pathway in which more than one gene has been altered or modified, thereby altering level and/or activity of the corresponding gene products/enzymes. In some cases the ability to " deregulate" a pathway (e.g., to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism arises from the particular phenomenon of microorganisms in which more than one enzyme (e.g., two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed a " cluster" or " gene cluster" In other cases, in order to deregulate a pathway, a number of genes must be deregulated in a series of sequential engineering steps.

To express the deregulated genes according to the invention, the DNA sequence encoding the polypeptide must be operably linked to regulatory sequences that control transcriptional expression in an expression vector and then, introduced into either microorganism. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene which is suitable for selection of cells that carry the expression vector.

The terms " overexpress" , " overexpressing" , " overexpressed" and

" overexpression" refer to expression of a gene product, in particular to enhancing the expression of a gene product at a level greater than that present prior to a genetic alteration of the starting microorganism. In some embodiments, a microorganism can be genetically altered (e.g., genetically engineered) to express a gene product at an increased level relative to that produced by the starting microorganism. Genetic alteration includes, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g., by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is

constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site or transcription terminator, increasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene using routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Another way to overexpress a gene product is to enhance the stability of the gene product to increase its life time.

The term "domain" refers to a set of amino acids conserved at specific positions along an alignment of sequences of evolutionarily related proteins. While amino acids at other positions can vary between homologues, amino acids that are highly conserved at specific positions indicate amino acids that are likely essential in the structure, stability or function of a protein. Identified by their high degree of conservation in aligned sequences of a family of protein homologues, they can be used as identifiers to determine if any polypeptide in question belongs to a previously identified polypeptide family.

The term " motif" or " consensus sequence" or " signature" refers to a short conserved region in the sequence of evolutionarily related proteins. Motifs are frequently highly conserved parts of domains, but may also include only part of the domain, or be located outside of conserved domain (if all of the amino acids of the motif fall outside of a defined domain).

Specialist databases exist for the identification of domains, for example, SMART (Schultz et al. (1998) Proc. Natl. Acad. Sci. USA 95, 5857-5864; Letunic et al. (2002) Nucleic Acids Res 30, 242-244), InterPro (Mulder et al., (2003) Nucl. Acids. Res. 31 , 315-318), Prosite (Bucher and Bairoch (1994), A generalized profile syntax for biomolecular sequences motifs and its function in automatic sequence interpretation. (In) ISMB-94; Proceedings 2nd International Conference on Intelligent Systems for Molecular Biology. Altman R., Brutlag D., Karp P., Lathrop R., Searls D., Eds., pp53-61 , AAAI Press, Menlo Park; Hulo et al.,

Nucl. Acids. Res. 32:D134-D137, (2004)), or Pfam (Bateman et al., Nucleic Acids Research 30(1 ): 276-280 (2002) & The Pfam protein families database: R.D. Finn, J. Mistry, J. Tate, P. Coggill, A. Heger, J.E. Pollington, O.L. Gavin, P. Gunesekaran, G. Ceric, K. Forslund, L. Holm, E.L. Sonnhammer, S.R. Eddy, A. Bateman Nucleic Acids Research (2010) Database Issue 38:D21 1 -222). A set of tools for in silico analysis of protein sequences is available on the ExPASy proteomics server (Swiss Institute of Bioinformatics (Gasteiger et al., ExPASy: the proteomics server for in-depth protein knowledge and analysis, Nucleic Acids Res. 31 :3784-3788(2003)). Domains or motifs may also be identified using routine techniques, such as by sequence alignment.

Methods for the alignment of sequences for comparison are well known in the art, such methods include GAP, BESTFIT, BLAST, FASTA and T FAST A. GAP uses the algorithm of Needleman and Wunsch ((1970) J Mol Biol 48: 443-453) to find the global (i.e. spanning the complete sequences) alignment of two sequences that maximizes the number of matches and minimizes the number of gaps. The BLAST algorithm (Altschul et al. (1990) J Mol Biol 215: 403-10) calculates percent sequence identity and performs a statistical analysis of the similarity between the two sequences. The software for performing BLAST analysis is publicly available through the National Centre for Biotechnology Information (NCBI).

Homologues may readily be identified using, for example, the ClustalW multiple sequence alignment algorithm (version 1.83), with the default pairwise alignment parameters, and a scoring method in percentage. Global percentages of similarity and identity may also be determined using one of the methods available in the MatGAT software package (Campanella et al., BMC Bioinformatics. 2003 Jul 10;4:29. MatGAT: an application that generates similarity/identity matrices using protein or DNA sequences.). Minor manual editing may be performed to optimize alignment between conserved motifs, as would be apparent to a person skilled in the art. Furthermore, instead of using full-length sequences for the identification of homologues, specific domains may also be used. The sequence identity values may be determined over the entire nucleic acid or amino acid sequence or over selected domains or conserved motif(s), using the programs mentioned above using the default parameters. For local alignments, the Smith-Waterman algorithm is particularly useful (Smith TF, Waterman MS (1981 ) J. Mol. Biol 147(1 ); 195-7).

Typically, this involves a first BLAST involving BLASTing a query sequence against any sequence database, such as the publicly available NCBI database. BLASTN or TBLASTX (using standard default values) are generally used when starting from a nucleotide sequence, and BLASTP or TBLASTN (using standard default values) when starting from a protein sequence. The BLAST results may optionally be filtered. The full-length sequences of either the filtered results or non-filtered results are then BLASTed back (second BLAST) against sequences from the organism from which the query sequence is derived. The results of the first and second BLASTS are then compared. A paralogue is identified if a high-ranking hit from the first blast is from the same species as from which the query sequence is derived, a BLAST back then ideally results in the query sequence amongst the highest hits; an orthologue is identified if a high-ranking hit in the first BLAST is not from the same species as from which the query sequence is derived, and preferably results upon BLAST back in the query sequence being among the highest hits. High-ranking hits are those having a low E-value. The lower the E-value, the more significant the score (or in other words the lower the chance that the hit was found by chance). Computation of the E-value is well known in the art. In addition to E-values, comparisons are also scored by percentage identity. Percentage identity refers to the number of identical nucleotides (or amino acids) between the two compared nucleic acid (or polypeptide) sequences over a particular length. In the case of large families, ClustalW may be used, followed by a neighbour joining tree, to help visualize clustering of related genes and to identify orthologues and paralogues.

The term " sequence identity" between two nucleic acid sequences is understood as meaning the percent identity of the nucleic acid sequence over in each case the entire sequence length which is calculated by alignment with the aid of the program algorithm

GAP (Wisconsin Package Version 10.0, University of Wisconsin, Genetics Computer Group

(GCG), Madison, USA), setting the following parameters:

Gap Weight: 12 Length Weight: 4

Average Match: 2,912 Average Mismatch :-2,003

The term " sequence identity" between two amino acid sequences is understood as meaning the percent identity of the nucleic acid sequence over in each case the entire sequence length which is calculated by alignment with the aid of the program algorithm GAP (Wisconsin Package Version 10.0, University of Wisconsin, Genetics Computer Group (GCG), Madison, USA), setting the following parameters:

Gap Weight: 8 Length Weight: 2

Average Match: 2,912 Average Mismatch:-2,003

The term "hybridisation" as defined herein is a process wherein substantially homologous complementary nucleotide sequences anneal to each other. The hybridisation process can occur entirely in solution, i.e. both complementary nucleic acids are in solution. The hybridisation process can also occur with one of the complementary nucleic acids immobilised to a matrix such as magnetic beads, Sepharose beads or any other resin. The hybridisation process can furthermore occur with one of the complementary nucleic acids immobilised to a solid support such as a nitro-cellulose or nylon membrane or immobilised by e.g. photolithography to, for example, a siliceous glass support (the latter known as nucleic acid arrays or microarrays or as nucleic acid chips). In order to allow hybridisation to occur, the nucleic acid molecules are generally thermally or chemically denatured to melt a double strand into two single strands and/or to remove hairpins or other secondary structures from single stranded nucleic acids.

The term " stringency" refers to the conditions under which a hybridisation takes place. The stringency of hybridisation is influenced by conditions such as temperature, salt concentration, ionic strength and hybridisation buffer composition. Generally, low stringency conditions are selected to be about 30°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Medium stringency conditions are when the temperature is 20°C below T_m, and high stringency conditions are when the temperature is 10°C below T_m. High stringency hybridisation conditions are typically used for isolating hybridising sequences that have high sequence similarity to the target nucleic acid sequence. However, nucleic acids may deviate in sequence and still encode a substantially identical polypeptide, due to the degeneracy of the genetic code. Therefore medium stringency hybridisation conditions may sometimes be needed to identify such nucleic acid molecules.

The Tm is the temperature under defined ionic strength and pH, at which 50% of the target sequence hybridises to a perfectly matched probe. The T_m is dependent upon the solution conditions and the base composition and length of the probe. For example, longer sequences hybridise specifically at higher temperatures. The maximum rate of hybridisation is obtained from about 16°C up to 32°C below T_m. The presence of monovalent cations in the hybridisation solution reduce the electrostatic repulsion between the two nucleic acid strands thereby promoting hybrid formation; this effect is visible for sodium concentrations of up to 0.4M (for higher concentrations, this effect may be ignored). Formamide reduces the melting temperature of DNA-DNA and DNA-RNA duplexes with 0.6 to 0.7°C for each percent formamide, and addition of 50% formamide allows hybridisation to be performed at 30 to 45°C, though the rate of hybridisation will be lowered. Base pair mismatches reduce the hybridisation rate and the thermal stability of the duplexes. On average and for large probes, the Tm decreases about 1 °C per % base mismatch. The T_m may be calculated using the following equations, depending on the types of hybrids:

1 ) DNA-DNA hybrids (Meinkoth and Wahl, Anal. Biochem., 138: 267-284, 1984):

T_m= 81 .5°C + 16.6xlogi₀[Na⁺]^a + 0.41x%[G/C^b] - 500x[L^c]-¹ - 0.61x% formamide

2) DNA-RNA or RNA-RNA hybrids:

T_m= 79.8°C+ 18.5 (logi₀[Na⁺]^a) + 0.58 (%G/C^b) + 1 1 .8 (%G/C^b)² - 820/L^c

3) oligo-DNA or oligo-RNA^d hybrids:

For <20 nucleotides: T_m= 2 (l_n)

For 20- 35 nucleotides: T_m= 22 + 1 .46 (l_n)

a or for other monovalent cation, but only accurate in the 0.01- 0.4 M range.

b only accurate for %GC in the 30% to 75% range.

c L = length of duplex in base pairs.

d oligo, oligonucleotide; l_n, = effective length of primer = 2^χ(ηο. of G/C)+(no. of A T).

Non-specific binding may be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein containing solutions, additions of heterologous RNA, DNA, and SDS to the hybridisation buffer, and treatment with Rnase. For non-homologous probes, a series of hybridizations may be performed by varying one of (i) progressively lowering the annealing temperature (for example from 68°C to 42°C) or (ii) progressively lowering the formamide concentration (for example from 50% to 0%). The skilled artisan is aware of various parameters which may be altered during hybridisation and which will either maintain or change the stringency conditions.

Besides the hybridisation conditions, specificity of hybridisation typically also depends on the function of post-hybridisation washes. To remove background resulting from nonspecific hybridisation, samples are washed with dilute salt solutions. Critical factors of such washes include the ionic strength and temperature of the final wash solution: the lower the salt concentration and the higher the wash temperature, the higher the stringency of the wash. Wash conditions are typically performed at or below hybridisation stringency. A positive hybridisation gives a signal that is at least twice of that of the background.

Generally, suitable stringent conditions for nucleic acid hybridisation assays or gene amplification detection procedures are as set forth above. More or less stringent conditions may also be selected. The skilled artisan is aware of various parameters which may be altered during washing and which will either maintain or change the stringency conditions. For example, typical high stringency hybridisation conditions for DNA hybrids longer than 50 nucleotides encompass hybridisation at 65°C in 1x SSC or at 42°C in 1x SSC and 50% formamide, followed by washing at 65°C in 0.3x SSC. Examples of medium stringency hybridisation conditions for DNA hybrids longer than 50 nucleotides encompass

hybridisation at 50°C in 4x SSC or at 40°C in 6x SSC and 50% formamide, followed by washing at 50°C in 2x SSC. The length of the hybrid is the anticipated length for the hybridising nucleic acid. When nucleic acids of known sequence are hybridised, the hybrid length may be determined by aligning the sequences and identifying the conserved regions described herein. 1 xSSC is 0.15M NaCI and 15mM sodium citrate; the hybridisation solution and wash solutions may additionally include 5x Denhardt's reagent, 0.5-1.0% SDS, 100 μ g/ml denatured, fragmented salmon sperm DNA, 0.5% sodium pyrophosphate.

For the purposes of defining the level of stringency, reference can be made to Sambrook et al. (2001) Molecular Cloning: a laboratory manual, 3^rd Edition, Cold Spring Harbor

Laboratory Press, CSH, New York or to Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989 and yearly updates).

" Homologues" of a protein encompass peptides, oligopeptides, polypeptides, proteins and enzymes having amino acid substitutions, deletions and/or insertions relative to the unmodified protein in question and having similar biological and functional activity as the unmodified protein from which they are derived.

A deletion refers to removal of one or more amino acids from a protein.

An insertion refers to one or more amino acid residues being introduced into a

predetermined site in a protein. Insertions may comprise N-terminal and/or C-terminal fusions as well as intra-sequence insertions of single or multiple amino acids. Generally, insertions within the amino acid sequence will be smaller than N- or C-terminal fusions, of the order of about 1 to 10 residues. Examples of N- or C-terminal fusion proteins or peptides include the binding domain or activation domain of a transcriptional activator as used in the yeast two-hybrid system, phage coat proteins, (histidine)-6-tag, glutathione S- transferase-tag, protein A, maltose-binding protein, dihydrofolate reductase, Tag* 100 epitope, c-myc epitope, FLAG^®-epitope, lacZ, CMP (calmodulin-binding peptide), HA epitope, protein C epitope and VSV epitope. A substitution refers to replacement of amino acids of the protein with other amino acids having similar properties (such as similar hydrophobicity, hydrophilicity, antigenicity, propensity to form or break a -helical structures or β -sheet structures). Amino acid substitutions are typically of single residues, but may be clustered depending upon functional constraints placed upon the polypeptide and may range from 1 to 10 amino acids; insertions will usually be of the order of about 1 to 10 amino acid residues. The amino acid substitutions are preferably conservative amino acid substitutions. Conservative substitution tables are well known in the art (see for example Creighton (1984) Proteins. W.H. Freeman and Company (Eds) and Table 1 below). Table 1 : Examples of conserved amino acid substitutions

Reference herein to an " endogenous" gene not only refers to the gene in question as found in an organism in its natural form (i.e., without there being any human intervention), but also refers to that same gene (or a substantially homologous nucleic acid/gene) in an isolated form subsequently (re)introduced into a microorganism (a transgene). For example, a transgenic microorganism containing such a transgene may encounter a substantial reduction of the transgene expression and/or substantial reduction of expression of the endogenous gene. The isolated gene may be isolated from an organism or may be manmade, for example by chemical synthesis.

The terms " orthologues" and " paralogues" encompass evolutionary concepts used to describe the ancestral relationships of genes. Paralogues are genes within the same species that have originated through duplication of an ancestral gene; orthologues are genes from different organisms that have originated through speciation, and are also derived from a common ancestral gene.

The term " splice variant" as used herein encompasses variants of a nucleic acid sequence in which selected introns and/or exons have been excised, replaced, displaced or added, or in which introns have been shortened or lengthened. Such variants will be ones in which the biological activity of the protein is substantially retained; this may be achieved by selectively retaining functional segments of the protein. Such splice variants may be found in nature or may be manmade. Methods for predicting and isolating such splice variants are well known in the art (see for example Foissac and Schiex (2005) BMC Bioinformatics 6: 25).

The term " vector" , preferably, encompasses phage, plasmid, fosmid, viral vectors as well as artificial chromosomes, such as bacterial or yeast artificial chromosomes. Moreover, the term also relates to targeting constructs which allow for random or site- directed integration of the targeting construct into genomic DNA. Such target constructs, preferably, comprise DNA of sufficient length for either homologous or heterologous recombination as described in detail below. The vector encompassing the polynucleotide of the present invention, preferably, further comprises selectable markers for propagation and/or selection in a recombinant microorganism. The vector may be incorporated into a recombinant microorganism by various techniques well known in the art. If introduced into a recombinant microorganism, the vector may reside in the cytoplasm or may be incorporated into the genome. In the latter case, it is to be understood that the vector may further comprise nucleic acid sequences which allow for homologous recombination or heterologous insertion. Vectors can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. The terms " transformation" and

" transfection" , conjugation and transduction, as used in the present context, are intended to comprise a multiplicity of prior-art processes for introducing foreign nucleic acid (for example DNA) into a recombinant microorganism, including calcium phosphate, rubidium chloride or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, carbon-based clusters, chemically mediated transfer, electroporation or particle bombardment. Methods for many species of microorganisms are readily available in the literature, for example, in Turgeon (2010) Molecular and cell biology methods for fungi, p3-9, in Koushki, MM et al., (201 1), AFRICAN JOURNAL OF

BIOTECHNOLOGY Vol.10 (41): p7939-7948, in Coyle et al. (2010) Appl Environ Microbiol 76:3898- 3903, in Current Protocols in Molecular Biology, Chapter 13. Eds Ausubel F.M. et al. Wiley & Sons, U.K., and in Genome Analysis: A Laboratory Manual, Cloning Systems. Volume 3. Edited by Birren B, Green ED, Klapholz S, Myers RM, Riethman H, Roskams J. New York: Cold Spring Harbor Laboratory Press; 1999:297-565. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

In a first aspect, the present invention provides polypeptide encoding nucleic acid sequences and polypeptides which can be used to support the production of cornexistin and/or hydroxycornexistin in microorganisms. As used herein, cornexistin and

hydroxycornexistin synthesis encompasses all steps of the biosynthesis of cornexistin and/or hydroxycornexistin. Accordingly, a polypeptide which is involved in the synthesis of cornexistin and/or hydroxycornexistin may either convert a substrate into cornexistin or hydroxycornexistin or may produce any of the precursors which occur in the cornexistin and hydroxycornexistin biosynthesis. Preferably, the polypeptides encoded by the

polynucleotides of the present invention shall be capable of increasing the amount of cornexistin and/or hydroxycornexistin or a precursor thereof upon expression in an organism, preferably a recombinant microorganism as specified elsewhere herein. Such an increase is, preferably, statistically significant when compared to a control organism which lacks expression of the polynucleotide of the present invention Preferably the control organism is of the same species and even more preferred belongs to the same strain that was used to construct the recombinant microorganism. Whether an increase is significant can be determined by statistical tests well known in the art including, e.g., Student^'s t-test. More preferably, the increase is an increase of the amount of cornexistin and/or hydroxycornexistin of at least 5%, at least 10%, at least 15%, at least 20% or at least 30% compared to said control. Suitable assays to identify and measure the amount of cornexistin and hydroxycornexistin are known by the person skilled in the art and are described for example in US4897104, US4990178, US5424278 and in US14/084030.

The provided polynucleotides recombinant polynucleotides can either be isolated from their natural genomic environment, e.g. from the genome of Talaromyces stipitatus as depositied under CBS H-7835 and genome of Bipolaris maydis as depositied under ATCC 48332, respectively, or deposited unter ATCC10500, modified after their isolation or produced artificially from pure sequence information.

A natural source of polynucleotides of the invention are preferably cornexistin or

hydroycornexistin producing fungi and related species, but also non producing fungi which lack parts of the metabolic pathway for the production of cornexistin and/or

hydroycornexistin are potential sources. Such fungi can, for example, be found in the group consisting of the genus Talaromyces, the genus Bipolaris, the genus Paecilomyces, the genus Byssochlamys, the genus Thermoascus and the genus Monascus for example the species Byssochlamys verrucosa, Byssochlamys nivea, Paecilomyces divaricatus,

Paecilomyces variotii, Thermoascus crustaceus, Thermoascus thermophilus and

Thermoascus aurantiacus.

Of particular interest are fungi of the species: Talaromyces stipitatus, Talaromyces thermophiles, Bipolaris maydis, Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae, Paecilomyces divaricatus and Byssochlamys verrucosa. Strains of these species are deposited, for example, at the CBS Fungal Biodiversity Centre (CBS) or the ATCC as: Talaromyces stipitatus CBS H-7835 or ATCC10500, isolated from decaying wood in

Louisiana USA, Talaromyces thermophilus ATCC 16461 (Penicillium dupontii) isolated from rotting guayule shrub in California USA, Bipolaris maydis C5 ATCC 48332 deposited by OC Yoder, Byssochlamys verrucosa CBS 605.74 isolated in Australia, Paecilomyces divaricatus CBS 284.48 isolated in the USA and Paecilomyces divaricatus CBS 1 10429 isolated in Mexico. A most preferred strain of Paecilomyces variotii has been deposited under Ministry of International Trade and Industry Japan deposit number FERM BP-1351 and deposited at the American Type Culture Collection under accession number ATTC 74268, both being derived from Paecilomyces variotii Bainier SANK 21086, having been isolated from deer faeces collected in Canada.

Further information for the selection of suitable organisms can, for example, be found in Mutsuo Nakajima et al.; CORNEXISTIN: A NEW FUNGAL METABOLITE WITH

HERBICIDAL ACTIVITY; THE JOURNAL OF ANTIBIOTICS, VOL.44 NO. 10, 1991 : page 1065-1072, in US4897104, US4990178, US5424278 and in R.A. Samson et al. "Polyphasic taxonomy of the heat resistant ascomycete genus Byssochlamys and its Paecilomyces anamorphs" Persoonia 22, 2009: pages 14- 27.

Further sources to identify suitable variants of polynucleotide and polypeptide sequences are public databases. The polynucleotide and polypeptides sequences for the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, geneR disclosed herein have either been

downloaded from public databases or represent synthetic variants of these sequences. However, the term " variants" or " variant" should not be limited to synthetic variants, but is also intended to include variants which occour in nature. Examples, but not excluding others, for such variants can be found in the published genomes of Bipolaris vitoriae FI3, Bipolaris zeicola 26-R-13, Bipolaris maydis C5 ATCC 48332 and Bipolaris maydis

ATCC48331. The sequence information of polynucleotides isolated from the natural sources described above can be used to isolate homologous polynucleotides and allelic or splice variants of the polynucleotide and polypeptide sequences disclosed herein. Further variants of the disclosed polynucleotides can be constructed, e.g. by adapting the codon usage of polypeptide encoding nucleic acid sequences to the codon usage of a preferred species of microorganism. For example, a person having skill in the art will be able to design variants of the polynucleotides described herein, by using the information on polypeptides described herein by designing polynucleotides of different codon usage to encode, for example, but not excluding others, a polypeptide disclosed in one of the Figures 1 to 8 and/or disclosed in the sequence listing. Further variants of the polynucleotides of the invention can be created by adding, deleting one or more polynucleotides from a polynucleotide, e.g. by shortening spacer regions between expression cassettes, by deleting introns, or deleting one or more codons of polypeptide encoding regions or complete functional elements of the polynucleotides, like complete, promoter, terminator or polypeptide encoding regions or complete expression cassettes. Alternatively, or in addition thereto, is is possible to create variants of the encoded polypeptide sequences, e.g. by introducing conserved amino acid substitutions or by adding or deleting one or more codons in order to enlarge or shorten the encoded polypeptides, or to create polypeptide fusions. Preferred polypeptide fusion comprise polypeptides for monitoring expression (e.g., green, yellow, blue or red fluorescent proteins, alkaline phosphatase and the like) or so called " tags" which may serve as a detectable marker or as an auxiliary measure for purification purposes. Tags for the different purposes are well known in the art and comprise FLAG-tags, 6-histidine-tags, MYC-tags and the like.

Variants in sequence identity and sequence length also encompass polynucleotides comprising a nucleic acid sequence which is capable of hybridizing to the aforementioned specific nucleic acid sequences, preferably, under stringent hybridization conditions.

Alternatively, polynucleotide variants are obtainable by PCR-based techniques such as mixed oligonucleotide primer- based amplification of DNA, i.e. using degenerated primers against conserved domains of the polypeptides of the present invention. Conserved domains of the polypeptide of the present invention may be identified by a sequence comparison of the nucleic acid sequences of the polynucleotides or the amino acid sequences of the polypeptides of the present invention. Oligonucleotides suitable as PCR primers as well as suitable PCR conditions are described in the accompanying Examples. As a template, DNA or cDNA from bacteria, fungi, plants or animals may be used.

Accordingly, the polynucleotide and amino acid sequence information disclosed herein and in the sequence listing, can be used to identify or create variants in sequence identity and sequence length comprising a nucleic acid sequence being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleic acid sequences and amino acid sequences disclosed herein, or can be used to identify or create sequence variants comprising a nucleic acid sequence or amino acid sequence having at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the sequence length of the respective nucleic acid sequence or amino acid sequence disclosed herein. Some embodiments of the invention use polynucleotide or polypeptide (also called nucleic acid sequences and amino acid sequences), which are at least least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but not identical to polynucleotide or polypeptide sequences which occure in nature.

The variants in sequence identity or sequence lenght referred to above may differ only in less than 1 1 , 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acids or nucleotides to the sequence as described by a sequence of SEQ ID NOs: 1 to 222 and SEQ ID NOs: 243 to 350 having the highest sequence identity to the respective variant. The differences are in the case of amino acid sequences preferably due to conservative amino acid substitutions, amino acid insertions or N- or C-terminal additions of amino acids in the case of nucleic acid

sequences, there are preferably due to silent mutations or codon optimization.

The variants in sequence identity referred to above, preferably, encode polypeptides retaining a significant extent, preferably, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the activity exhibited by a polypeptide encoded by at least one of SEQ ID NO: 13 for geneA, SEQ ID NO: 32 for geneB, SEQ ID NO: 51 for geneC, SEQ ID NO: 70 for geneD, SEQ ID NO: 89 for geneE, SEQ ID NO 108 for geneF, SEQ ID NO 127 for geneG, SEQ ID NO 146 for geneH, SEQ ID NO: 153 for genel, SEQ ID NO: 160 for geneJ, SEQ ID NO: 167 for geneK, SEQ ID NO: 174 for genel_, SEQ ID NO: 181 for geneM, SEQ ID NO: 188 for geneN, SEQ ID NO: 195 for geneO, SEQ ID NO: 202 for geneP, SEQ ID NO: 209 for geneQ, SEQ ID NO: 216 for geneR.

The activity can be tested by replacing the polynucleotide having the respective gene function in Paecilomyces divaricatus with a polynucleotide encoding the respective variant in sequence identity, culturing the recombinant Paecilomyces divaricatus cells under conditions which allow for the production of cornexistin, hydroxycornexistin or both and comparing the amount of cornexistin, hydroxycornexistin or both with the amount of the cornexistin, hydroxycornexistin or both produced by the non-recombinant Paecilomyces divaricatus cultured under the same conditions. Preferably the amount of cornexistin is compared for polypeptides involved in cornexistin biosynthesis, while the amount of hydroxycornexistin is compared for polypeptides involved in hydroxycornexistin biosynthesis. The activity of polypeptides involved in cornexistin and hydroxycornexistin biosynthesis is measured by comparing the amount of the produced cornexistin, or, preferably, the total amount of the produced cornexistin and hydroxycornexystin.

A polynucleotide to be tested will provide the same gene function, if the complemented Paecilomyces divaricatus strain will be able to produce cornexistin and/or hydroxycornexistin on a similar level than the Paecilomyces divaricatus strain used to construct the recombinant strain.

Polynucleotides and polypeptides providing geneA function:

Polynucleotides and polypeptides providing geneA function can be isolated from

Talaromyces stipitatus (SEQ ID NO: 1 and 2) and from Paecilomyces divaricatus SEQ ID NO: 13 and 14).

Variants of these polypeptides are for example, but not excluding others, .

a1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or

a2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or

a3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

a4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or

a5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO:

1 per primer, or

a6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) polypeptides comprising at least two of features a1 ), a2), a3), a4), a5) and a6);

Further variants of these polypeptides are for example, but not excluding others, .

a1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14, or

a2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14, 15, 16, 17, 18, and/or 19, or

a3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 13, or

a4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 13, or a5) polypeptides expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO:

13 per primer, or

14 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

Table 2 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12 and 14. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 2:

SEQ 2 3 4 5 6 7 8 9 10 11 12 14 ID NO:

2 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 51 %

3 100% 91 % 89% 90% 87% 88% 83% 83% 79% 79% 50%

4 - 100% 90% 90% 87% 88% 83% 83% 79% 79% 50%

5 - - 100% 89% 86% 87% 82% 82% 79% 78% 50%

6 - - - 100% 87% 86% 82% 83% 79% 79% 50%

7 - - - - 100% 84% 81 % 81 % 78% 79% 50%

8 - - - - - 100% 82% 82% 79% 78% 50%

9 - - - - - - 100% 79% 78% 78% 48%

10 - - - - - - - 100% 77% 77% 48%

1 1 - - - - - - - - 100% 76% 47%

12 - - - - - - - - - 100% 48%

14 - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneA function can also be isolated from Bipolaris maydis (SEQ ID NO: 243 and 244), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species.

Variants of these polypeptides are for example, but not excluding others, .

a1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

a2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or

a3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

a4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or a5) polypeptides expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO:

243 per primer, or

244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) polypeptides comprising at least two of features a1), a2), a3), a4), a5) and a6);

Table 2a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253, 254 and 14. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX:

EBLOSUM62

Table 2a:

SEQ 244 245 246 247 248 249 250 251 252 253 254 14 ID NO:

244 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 50%

245 100% 91 % 90% 90% 88% 87% 83% 82% 80% 79% 48%

246 - 100% 90% 90% 87% 87% 83% 84% 80% 80% 48%

247 - - 100% 88% 86% 86% 83% 83% 79% 79% 48%

248 - - - 100% 86% 86% 82% 83% 78% 78% 48%

249 - - - - 100% 85% 81 % 81 % 79% 79% 48%

250 - - - - - 100% 82% 81 % 78% 79% 48%

251 - - - - - - 100% 80% 77% 78% 47%

252 - - - - - - - 100% 78% 78% 47%

253 - - - - - - - - 100% 76% 44%

254 - - - - - - - - - 100% 46%

14 - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneB function:

Polynucleotides and polypeptides providing geneB function can be isolated from Talaromyces stipitatus (SEQ ID NO: 20 and 21 ) and from Paecilomyces divaricatus SEQ ID NO: 32 and 33).

Variants of these polypeptides are for example, but not excluding others, .

b1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or

b2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or b3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

b4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 20, or b5) polypeptides expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO:

20 per primer, or

b6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) polypeptides comprising at least two of features b1 ), b2), b3), b4), b5) and b6);

b1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33, or

b2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 33, 34, 35, 36, 37, and/or 38, or

b3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 33, or

b4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 32, or

b5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

32 per primer, or

33 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

Table 3 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 33. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 3:

SEQ 21 22 23 24 25 26 27 28 29 30 31 33 ID NO:

21 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 40%

22 - 100% 93% 91 % 91 % 89% 90% 88% 87% 84% 85% 42%

23 - - 100% 92% 94% 90% 90% 88% 85% 84% 84% 43%

24 - - - 100% 93% 90% 89% 87% 86% 85% 85% 41 %

25 - - - - 100% 91 % 92% 91 % 86% 87% 87% 43%

26 - - - - - 100% 91 % 90% 89% 89% 89% 41 % 27 - - - - - - 100% 90% 90% 89% 90% 41 %

28 - - - - - - 100% 89% 93% 93% 41 %

29 - - - - - - 100% 92% 93% 39%

30 - - - - - - - 100% 96% 40%

31 - - - - - - - - 100% 39%

33 - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneB function can also be isolated from Bipolaris maydis (SEQ ID NO: 243, 244, 256 and 340), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species.

b1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or

b2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

b3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

b4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 255, or expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 339, or

b5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer, or polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

polypeptides comprising at least two of features b1), b2), b3), b4), b5) and b6);

Table 3a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, 266 and 33 and pairwise alignments of SEQ ID NOs: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, 350 and 33. The

parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 3a:

SEQ 256 257 258 259 260 261 262 263 264 265 266 340 33

ID

NO:

256 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 52% 50%

257 - 100% 93% 92% 90% 90% 87% 86% 87% 82% 83% 53% 51 %

258 - - 100% 93% 93% 90% 90% 86% 90% 83% 83% 52% 50%

259 - - - 100% 90% 89% 86% 86% 88% 84% 86% 50% 50%

260 - - - - 100% 89% 88% 88% 86% 83% 82% 50% 50%

261 - - - - - 100% 90% 85% 87% 86% 86% 50% 50%

262 - - - - - - 100% 83% 87% 82% 86% 49% 48%

263 - - - - - - - 100% 86% 89% 86% 51 % 46%

264 - - - - - - - - 100% 85% 87% 50% 48%

265 - - - - - - - - - 100% 90% 51 % 46%

266 - - - - - - - - - - 100% 48% 48%

340 - - - - - - - - - - - 100% 50%

33 - - - - - - - - - - - - 100%

SEQ 340 341 342 343 344 345 346 347 348 349 350 256 33

ID

NO:

340 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 52% 50%

341 - 100% 91 % 93% 93% 90% 86% 88% 85% 83% 84% 51 % 50%

342 - - 100% 90% 90% 91 % 87% 85% 87% 83% 83% 51 % 50%

343 - - - 100% 91 % 87% 88% 87% 87% 84% 86% 51 % 50%

344 - - - - 100% 90% 88% 87% 86% 85% 85% 53% 50%

345 - - - - - 100% 88% 89% 87% 86% 86% 51 % 50%

346 - - - - - - 100% 89% 86% 87% 87% 50% 50%

347 - - - - - - - 100% 85% 88% 89% 50% 49%

348 - - - - - - - - 100% 86% 90% 49% 49%

349 - - - - - - - - - 100% 90% 49% 50%

350 - - - - - - - - - - 100% 49% 48%

256 - - - - - - - - - - - 100% 50%

33 - - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneC function:

Polynucleotides and polypeptides providing geneC function can be isolated from Talaromyces stipitatus (SEQ ID NO: 39 and 40) and from Paecilomyces divaricatus SEQ ID NO: 51 and 52).

Variants of these polypeptides are for example, but not excluding others, . c1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or

c2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or c3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 39, or

c4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or

c5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

39 per primer, or

c6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

40 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or

c7) polypeptides comprising at least two of features c1 ), c2), c3), c4), c5) and c6); Further variants of these polypeptides are for example, but not excluding others, .

c1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52, or

c2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52, 53, 54, 55, 56, and/or 57, or

c3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 51 , or

c4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 51 , or

c5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

51 per primer, or

52 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or

c7) polypeptides comprising at least two of features c1 ), c2), c3), c4), c5) and c6); Table 4 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50 and 52. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 4:

SEQ 40 41 42 43 44 45 46 47 48 49 50 52

ID NO:

40 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 48%

41 100% 91 % 89% 89% 87% 87% 84% 82% 79% 80% 48%

42 - 100% 91 % 89% 88% 87% 83% 84% 79% 80% 46%

43 - - 100% 90% 88% 87% 84% 82% 79% 80% 45%

44 - - - 100% 88% 87% 84% 81 % 80% 80% 47%

45 - - - - 100% 85% 84% 84% 82% 81 % 45%

46 - - - - - 100% 83% 85% 81 % 80% 45%

47 - - - - - - 100% 81 % 83% 80% 47%

48 - - - - - - - 100% 79% 79% 44%

49 - - - - - - - - 100% 80% 44%

50 - - - - - - - - - 100% 44%

52 - - - - - - - - - - 100% Polynucleotides and polypeptides providing geneC function can also be isolated from Bipolaris maydis (SEQ ID NO: 267 and 268), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species.

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

c2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277 and 278, or

c3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

c4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or c5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

267 per primer, or

268 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or

c7) polypeptides comprising at least two of features c1 ), c2), c3), c4), c5) and c6); Table 4a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 269, 270, 271 , 272, 273, 274, 275, 276, 277, 278 and 52. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX:

EBLOSUM62

Table 4a:

SEQ 268 269 270 271 272 273 274 275 276 277 278 52 ID NO:

268 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 60%

269 100% 91 % 90% 90% 88% 87% 83% 84% 81 % 79% 59%

270 - 100% 89% 90% 86% 87% 85% 84% 80% 79% 59%

271 - - 100% 88% 88% 87% 84% 83% 80% 80% 57%

272 - - - 100% 87% 87% 85% 84% 81 % 79% 58%

273 - - - - 100% 89% 83% 84% 82% 81 % 59%

274 - - - - - 100% 82% 85% 83% 81 % 59%

275 - - - - - - 100% 81 % 82% 77% 55%

276 - - - - - - - 100% 78% 78% 54%

277 - - - - - - - - 100% 80% 54%

278 - - - - - - - - - 100% 54%

52 - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneD function:

Polynucleotides and polypeptides providing geneD function can be isolated from Talaromyces stipitatus (SEQ ID NO: 58 and 59) and from Paecilomyces divaricatus SEQ ID NO: 70 and 76).

Variants of these polypeptides are for example, but not excluding others, .

d1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or

d2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or d3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

d4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 58, or

d5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

58 per primer, or

d6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) polypeptides comprising at least two of features d1 ), d2), d3), d4), d5) and d6); Further variants of these polypeptides are for example, but not excluding others, .

d1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71 , or d2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71 , 72, 73, 74, 75, and/or 76, or

d3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 70, or

d4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 70, or

d5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

70 per primer, or

71 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 4, or

d7) polypeptides comprising at least two of features d1 ), d2), d3), d4), d5) and d6);

Table 5 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69 and 71. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 5:

SEQ 59 60 61 62 63 64 65 66 67 68 69 71

ID NO:

59 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 54%

60 100% 91 % 89% 91 % 88% 88% 84% 82% 80% 80% 52%

61 - 100% 90% 91 % 89% 88% 83% 83% 78% 80% 52%

62 - - 100% 88% 85% 86% 81 % 84% 79% 78% 53%

63 - - - 100% 87% 87% 84% 84% 81 % 81 % 52%

64 - - - - 100% 85% 81 % 81 % 80% 79% 52%

65 - - - - - 100% 82% 81 % 79% 78% 52%

66 - - - - - - 100% 79% 80% 79% 49%

67 - - - - - - - 100% 78% 78% 49%

68 - - - - - - - - 100% 78% 46%

69 - - - - - - - - - 100% 48%

71 - - - - - - - - - - 100% Polynucleotides and polypeptides providing geneD function can also be isolated from Bipolaris maydis (SEQ ID NO: 279 and 280), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species.

d 1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or d2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289 and 290, or

d3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 279, or

d4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 279, or d5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or

d6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 4, or

d7) polypeptides comprising at least two of features d 1 ), d2), d3), d4), d5) and d6);

Table 5a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, 290 and 71 . The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX:

EBLOSUM62 Table 5a:

SEQ 280 281 282 283 284 285 286 287 288 289 290 71 ID NO:

280 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 63%

281 - 100% 92% 90% 89% 87% 87% 82% 83% 79% 78% 60%

282 - - 100% 90% 90% 88% 87% 86% 84% 80% 79% 60%

283 - - - 100% 89% 88% 86% 86% 84% 78% 80% 59%

284 - - - - 100% 88% 88% 85% 82% 81 % 80% 59%

285 - - - - - 100% 84% 82% 83% 79% 81 % 59%

286 - - - - - - 100% 82% 81 % 79% 78% 57%

287 - - - - - - - 100% 81 % 78% 80% 56%

288 - - - - - - - - 100% 78% 81 % 55%

289 - - - - - - - - - 100% 77% 55%

290 - - - - - - - - - - 100% 53%

71 - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneE function:

Polynucleotides and polypeptides providing geneE function can be isolated from

Talaromyces stipitatus (SEQ ID NO: 77 and 78) and from Paecilomyces divaricatus SEQ ID NO: 89 and 90).

Variants of these polypeptides are for example, but not excluding others, .

e1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or

e2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or e3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 77, or

e4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 77, or

e5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or

e6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) polypeptides comprising at least two of features e1 ), e2), e3), e4), e5) and e6).

e1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 91 , or

e2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90, 91 , 92, 93, 94, and/or 95, or

e3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 89, or

e4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 89, or

e5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 89 per primer, or

e6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 5, or

e7) polypeptides comprising at least two of features e1 ), e2), e3), e4), e5) and e6);

Table 6 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88 and 90. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62 Table 6:

SEQ 78 79 80 81 82 83 84 85 86 87 88 90 ID NO:

78 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 40%

79 100% 90% 90% 89% 85% 88% 85% 85% 77% 80% 41 %

80 - 100% 88% 90% 88% 88% 83% 85% 82% 80% 39%

81 - - 100% 88% 84% 87% 83% 86% 82% 79% 40%

82 - - - 100% 87% 87% 82% 85% 81 % 80% 42%

83 - - - - 100% 84% 80% 82% 81 % 81 % 40%

84 - - - - - 100% 78% 84% 80% 79% 41 %

85 - - - - - - 100% 84% 76% 80% 39%

86 - - - - - - - 100% 80% 80% 39%

87 - - - - - - - - 100% 83% 41 %

88 - - - - - - - - - 100% 41 %

90 - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneE function can also be isolated from Bipolaris maydis (SEQ ID NO: 291 and 292), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species.

e1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

e2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 and 302, or

SEQ ID NO: 291 , or

e4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 291 , or e5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or

e6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 5, or

Table 6a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 , 302 and 90. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 6a:

SEQ 292 293 294 295 296 297 298 299 300 301 302 90 ID NO:

292 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 41 %

293 100% 92% 91 % 90% 88% 89% 87% 84% 81 % 82% 39%

294 - 100% 89% 89% 88% 87% 84% 85% 81 % 82% 39%

295 - - 100% 88% 88% 87% 87% 82% 83% 82% 40%

296 - - - 100% 87% 86% 84% 84% 80% 81 % 40%

297 - - - - 100% 89% 84% 84% 84% 80% 40%

298 - - - - - 100% 83% 83% 81 % 79% 41 %

299 - - - - - - 100% 81 % 84% 84% 41 %

300 - - - - - - - 100% 83% 80% 39%

301 - - - - - - - - 100% 84% 38%

302 - - - - - - - - - 100% 39%

90 - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneF function:

Polynucleotides and polypeptides providing geneF function can be isolated from Talaromyces stipitatus (SEQ ID NO: 96 and 97) and from Paecilomyces divaricatus SEQ ID NO: 108 and 109).

Variants of these polypeptides are for example, but not excluding others, .

f1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or

f2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or

f3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

f4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or

f5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

96 per primer, or

f6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) polypeptides comprising at least two of features f1), f2), f3), f4), f5) and f6).

Further variants of these polypeptides are for example, but not excluding others, . f1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109 or

e2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, 1 10, 1 1 1 , 1 12, 1 13, and/or 1 14, or

f3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, or

f4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 108, or f5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

108 per primer, or

109 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 6, or

f7) polypeptides comprising at least two of features f1 ), f2), f3), f4), f5) and f6); Table 7 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, 107 and 109. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX:

EBLOSUM62

Table 7:

SEQ 97 98 99 100 101 102 103 104 105 106 107 109 ID NO:

97 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 44%

98 - 100% 91 % 89% 89% 86% 88% 82% 84% 78% 80% 43%

99 - - 100% 89% 89% 87% 87% 83% 82% 78% 79% 44%

100 - - - 100% 88% 86% 86% 82% 83% 79% 80% 42%

101 - - - - 100% 86% 86% 83% 83% 77% 77% 42%

102 - - - - - 100% 84% 79% 81 % 79% 81 % 44%

103 - - - - - - 100% 81 % 80% 75% 80% 41 %

104 - - - - - - - 100% 78% 77% 77% 41 %

105 - - - - - - - - 100% 76% 73% 41 %

106 - - - - - - - - - 100% 77% 42%

107 - - - - - - - - - - 100% 44%

109 - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneF function can also be isolated from Bipolaris maydis (SEQ ID NO: 303 and 304), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species.

Further variants of these polypeptides are for example, but not excluding others, f1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 or

e2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310, 31 1 , 312, 313 and 314, or

f3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

f4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 303, or f5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

303 per primer, or

304 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 6, or

f7) polypeptides comprising at least two of features f1), f2), f3), f4), f5) and f6);

Table 7a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 304, 305, 306, 307, 308, 309, 310, 31 1 , 312, 313, 314 and 109. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 7a:

SEQ 304 305 306 307 308 309 310 311 312 313 314 109 ID NO:

304 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 49%

305 - 100% 90% 90% 90% 86% 86% 82% 85% 81 % 76% 51 %

306 - - 100% 87% 90% 88% 87% 83% 84% 79% 78% 48%

307 - - - 100% 88% 85% 86% 81 % 85% 81 % 78% 48%

308 - - - - 100% 86% 85% 82% 83% 81 % 76% 50%

309 - - - - - 100% 83% 79% 81 % 78% 74% 48%

310 - - - - - - 100% 81 % 82% 77% 82% 47%

31 1 - - - - - - - 100% 80% 76% 75% 45%

312 - - - - - - - - 100% 78% 76% 47%

313 - - - - - - - - - 100% 77% 46%

314 - - - - - - - - - - 100% 43%

109 - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneG function:

Polynucleotides and polypeptides providing geneG function can be isolated from Talaromyces stipitatus (SEQ ID NO: 1 15 and 1 16) and from Paecilomyces divaricatus SEQ ID NO: 127 and 128). Variants of these polypeptides are for example, but not excluding others, .

g1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or

g2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, and/or 126, or

g3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

g4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15, or g5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or

g6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) polypeptides comprising at least two of features g1 ), g2), g3), g4), g5) and g6).

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128 or

g2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, 129, 130, 131 , 132, and/or 133, or

g3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 127, or

g4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 127, or g5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 127 per primer, or

g6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 7, or

g7) polypeptides comprising at least two of features g1 ), g2), g3), g4), g5) and g6);

Table 8 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, 126 and 128. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 8:

SEQ 116 117 118 119 120 121 122 123 124 125 126 128 ID NO:

1 16 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 43%

1 17 - 100% 91 % 89% 89% 86% 86% 82% 83% 79% 77% 43%

1 18 - - 100% 89% 90% 87% 87% 82% 82% 78% 78% 42%

1 19 - - - 100% 87% 85% 85% 82% 81 % 77% 78% 40%

120 - - - - 100% 85% 87% 83% 81 % 76% 79% 41 %

121 - - - - - 100% 84% 80% 79% 76% 74% 39%

122 - - - - - - 100% 79% 79% 76% 76% 40%

123 - - - - - - - 100% 79% 74% 75% 39%

124 - - - - - - - - 100% 76% 76% 40%

125 - - - - - - - - - 100% 72% 37%

126 - - - - - - - - - - 100% 38%

128 - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneG function can also be isolated from Bipolaris maydis (SEQ ID NO: 315 and 316), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species. g1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 or

g2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322, 323, 324, 325 and 326, or

g3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

g4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 315, or g5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or

g6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 7, or

Table 8a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 316, 317, 318, 319, 320, 321 , 322, 323, 324, 325 and 326 and 128. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 8a:

SEQ 316 317 318 319 320 321 322 323 324 325 326 128 ID NO:

316 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 42%

317 - 100% 91 % 89% 89% 87% 87% 83% 81 % 77% 79% 42%

318 - - 100% 90% 89% 87% 87% 81 % 82% 79% 79% 40%

319 - - - 100% 88% 85% 87% 82% 81 % 77% 77% 42%

320 - - - - 100% 86% 84% 82% 83% 78% 80% 40%

321 - - - - - 100% 84% 80% 80% 77% 77% 40%

322 - - - - - - 100% 80% 79% 75% 76% 41 %

323 - - - - - - - 100% 78% 75% 77% 41 %

324 - - - - - - - - 100% 74% 76% 41 %

325 - - - - - - - - - 100% 75% 38%

326 - - - - - - - - - - 100% 38%

128 - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneH function:

Polynucleotides and polypeptides providing geneH function can be isolated from

Talaromyces stipitatus (SEQ ID NO: 134 and 135) and from Paecilomyces divaricatus SEQ ID NO: 146 and 147).

Variants of these polypeptides are for example, but not excluding others, .

hi ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or

h3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

h4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or h5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

134 per primer, or

h6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) polypeptides comprising at least two of features hi ), h2), h3), h4), h5) and h6). Further variants of these polypeptides are for example, but not excluding others, .

hi ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147 or

h2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147, 148, 149, 150, 151 , and/or 152, or

h3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 146, or

h4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 146, or h5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

146 per primer, or

147 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 8, or

h7) polypeptides comprising at least two of features hi ), h2), h3), h4), h5) and h6);

Table 9 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, 145 and 147. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 9:

SEQ 135 136 137 138 139 140 141 142 143 144 145 147 ID NO:

135 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 41 %

136 - 100% 91 % 88% 88% 87% 87% 81 % 84% 79% 77% 39%

137 - - 100% 89% 88% 86% 87% 82% 82% 80% 78% 41 %

138 - - - 100% 88% 86% 86% 80% 81 % 78% 77% 40%

139 - - - - 100% 84% 85% 80% 82% 76% 77% 38%

140 - - - - - 100% 85% 80% 81 % 77% 76% 38%

141 - - - - - - 100% 80% 82% 75% 76% 40%

142 - - - - - - - 100% 77% 74% 72% 38%

143 - - - - - - - - 100% 74% 74% 39%

144 - - - - - - - - - 100% 74% 37%

145 - - - - - - - - - - 100% 36%

147 - - - - - - - - - - - 100%

Polynucleotides and polypeptides providing geneH function can also be isolated from Bipolaris maydis (SEQ ID NO: 327 and 328), Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species. Further variants of these polypeptides are for example, but not excluding others, .

h i ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 or

h2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337 and 338, or

h3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

h4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 327, or h5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or

h6) polypeptides being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 8, or

h7) polypeptides comprising at least two of features h i ), h2), h3), h4), h5) and h6);

Table 9a shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, 338 and 147. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 9a:

SEQ 328 329 330 331 332 333 334 335 336 337 338 147

ID NO:

328 100% 95% 95% 93% 93% 90% 90% 85% 85% 80% 80% 52%

329 - 100% 91 % 89% 90% 86% 86% 83% 83% 78% 80% 50%

330 - - 100% 90% 89% 87% 86% 83% 82% 79% 79% 51 %

331 - - - 100% 88% 85% 85% 83% 80% 77% 77% 49%

332 - - - - 100% 84% 84% 81 % 82% 78% 79% 49%

333 - - - - - 100% 82% 77% 77% 76% 77% 48%

334 - - - - - - 100% 81 % 82% 77% 77% 48%

335 - - - - - - - 100% 77% 74% 76% 47%

336 - - - - - - - - 100% 77% 76% 47%

337 - - - - - - - - - 100% 76% 44%

338 - - - - - - - - - - 100% 45%

147 - - - - - - - - - - - 100% Polynucleotides and polypeptides providing genel function:

Polynucleotides and polypeptides providing genel function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 153 and 154). Variants of these polypeptides are for example, but not excluding others, .

11 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 154, or

12) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 154, 155, 156, 157, 158, and/or 159, or

13) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153, or

14) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ I D NO: 153, or

15) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 153 per primer, or

i6) polypeptides comprising at least two of features i1 ), i2), i3), i4), and i5).

Table 10 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 154, 155, 156, 157, 158, and 159. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 10:

SEQ 154 155 156 157 158 159

ID NO:

154 100% 95% 95% 93% 90% 90%

155 - 100% 90% 88% 87% 86%

156 - - 100% 89% 88% 85%

157 - - - 100% 85% 84%

158 - - - - 100% 83%

159 - - - - - 100%

Polynucleotides and polypeptides providing geneJ function:

Polynucleotides and polypeptides providing geneJ function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 160 and 161 ).

Variants of these polypeptides are for example, but not excluding others, .

j1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 161 , or

j2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 161 , 162, 163, 164, 165, and/or 166, or

j3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 160, or

j4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 160, or j5) polypeptides expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 160 per primer, or

j6) polypeptides comprising at least two of features j 1 ), j2), j3), j4), and j5).

Table 1 1 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 161 , 162, 163, 164, 165, and 166. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 11 :

SEQ 161 162 163 164 165 166

ID NO:

161 100% 95% 95% 93% 90% 90%

162 - 100% 91 % 90% 86% 87%

163 - - 100% 89% 86% 86%

164 - - - 100% 85% 84%

165 - - - - 100% 82%

166 - - - - - 100%

Polynucleotides and polypeptides providing geneK function:

Polynucleotides and polypeptides providing geneK function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 167 and 168).

Variants of these polypeptides are for example, but not excluding others, .

k1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 168, or

k2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 168, 169, 170, 171 , 172, and/or 173, or

k3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 167, or

k4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 167, or k5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 167 per primer, or

k6) polypeptides comprising at least two of features k1 ), k2), k3), k4), and k5).

Table 12 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 168, 169, 170, 171 , 172, and 173. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62 Table 12:

SEQ 168 169 170 171 172 173

ID NO:

168 100% 95% 95% 93% 90% 90%

169 - 100% 91 % 89% 87% 87%

170 - - 100% 89% 87% 87%

171 - - - 100% 84% 87%

172 - - - - 100% 83%

173 - - - - - 100%

Polynucleotides and polypeptides providing geneL function:

Polynucleotides and polypeptides providing geneL function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 174 and 175).

Variants of these polypeptides are for example, but not excluding others, .

11 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 175, or

I2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 175, 176, 177, 178, 179, and/or 180, or

I3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 174, or

I4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ I D NO: 174, or

15) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 174 per primer, or

16) polypeptides comprising at least two of features 11 ), I2), I3), I4), and I5).

Table 13 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 175, 176, 177, 178, 179, and 180. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 13:

SEQ 175 176 177 178 179 180

ID NO:

175 100% 95% 95% 93% 90% 90%

176 - 100% 91 % 89% 87% 86%

177 - - 100% 89% 86% 86%

178 - - - 100% 86% 85%

179 - - - - 100% 83%

180 - - - - - 100% Polynucleotides and polypeptides providing geneM function: Polynucleotides and polypeptides providing geneM function can be isolated from Paecilomyces divaricatus SEQ ID NO: 181 and 182).

Variants of these polypeptides are for example, but not excluding others, .

ml ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 182, or

m2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 182, 183, 184, 185, 186, and/or 187, or

m3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or

m4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 181 , or m5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

181 per primer, or

m6) polypeptides comprising at least two of features ml ), m2), m3), m4), and m5).

Table 14 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 182, 183, 184, 185, 186, and 187. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 14:

SEQ 182 183 184 185 186 187

ID NO:

182 100% 95% 95% 93% 90% 90%

183 - 100% 91 % 89% 86% 87%

184 - - 100% 89% 85% 86%

185 - - - 100% 85% 85%

186 - - - - 100% 83%

187 - - - - - 100%

Polynucleotides and polypeptides providing geneN function:

Polynucleotides and polypeptides providing geneN function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 188 and 189).

Variants of these polypeptides are for example, but not excluding others, .

n 1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 189, or

n2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 189, 190, 191 , 192, 193, and/or 194, or

n3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 188, or n4) polypeptides expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 188, or n5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

188 per primer, or

n6) polypeptides comprising at least two of features n1 ), n2), n3), n4), and n5).

Table 15 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 189, 190, 191 , 192, 193, and 194. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 15:

SEQ 189 190 191 192 193 194

ID NO:

189 100% 95% 95% 93% 90% 90%

190 - 100% 90% 89% 87% 87%

191 - - 100% 90% 86% 86%

192 - - - 100% 86% 84%

193 - - - - 100% 83%

194 - - - - - 100%

Polynucleotides and polypeptides providing geneO function:

Polynucleotides and polypeptides providing geneO function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 195 and 196).

Variants of these polypeptides are for example, but not excluding others, .

o1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 196, or

02) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 196, 197, 198, 199, 200, and/or 201 , or

03) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 195, or

04) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 195, or

05) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 195 per primer, or

06) polypeptides comprising at least two of features o1 ), o2), o3), o4), and o5).

Table 16 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs 196, 197, 198, 199, 200, and 201. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite, #GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 16:

SEQ 196 197 198 199 200 201

ID NO:

196 100% 95% 95% 93% 90% 90%

197 - 100% 91 % 89% 87% 87%

198 - - 100% 90% 87% 87%

199 - - - 100% 86% 86%

200 - - - - 100% 84%

201 - - - - - 100%

Polynucleotides and polypeptides providing geneP function:

Polynucleotides and polypeptides providing geneP function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 202 and 208).

Variants of these polypeptides are for example, but not excluding others, .

p1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 203, or

p2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 203, 204, 205, 206, 207, and/or 208, or

p3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 202, or

p4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ I D NO: 202, or p5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 202 per primer, or

p6) polypeptides comprising at least two of features p1 ), p2), p3), p4), and p5). Table 17 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 203, 204, 205, 206, 207, and 208. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN: 10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62 Table 17:

SEQ 203 204 205 206 207 208

ID NO:

203 100% 95% 95% 93% 90% 90%

204 - 100% 91 % 89% 86% 86%

205 - - 100% 89% 87% 88%

206 - - - 100% 85% 86%

207 - - - - 100% 83%

208 - - - - - 100% Polynucleotides and polypeptides providing geneQ function:

Polynucleotides and polypeptides providing geneQ function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 209 and 210).

Variants of these polypeptides are for example, but not excluding others, .

q1 ) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, or

q2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, 21 1 , 212, 213, 214, and/or 215, or

q3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 209, or

q4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 209, or q5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 209 per primer, or

q6) polypeptides comprising at least two of features q1 ), q2), q3), q4), and q5).

Table 18 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 210, 21 1 , 212, 213, 214, and 215. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 18:

SEQ 210 211 212 213 214 215

ID NO:

210 100% 95% 95% 93% 90% 90%

21 1 - 100% 91 % 88% 87% 87%

212 - - 100% 89% 87% 87%

213 - - - 100% 86% 86%

214 - - - - 100% 83%

215 - - - - - 100%

Polynucleotides and polypeptides providing geneR function:

Polynucleotides and polypeptides providing geneR function can be isolated from

Paecilomyces divaricatus SEQ ID NO: 216 and 217).

Variants of these polypeptides are for example, but not excluding others, .

) polypeptides being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, or

r2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, 218, 219, 220, 221 , and/or 222, or

r3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 216, or

r4) polypeptides expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 216, or r5) polypeptides expressed from a polynucleotide which is obtainable via PCR on

genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO 216 per primer, or

r6) polypeptides comprising at least two of features r1 ), r2), r3), r4), and r5).

Table 19 shows the % sequence identity of pairwise sequence alignments of SEQ ID NOs: 217, 218, 219, 220, 221 , and 222. The parameters used for the pairwise sequence alignments are: Needleman-Wunsch algorithm of the EMBOSS Software Suite,

#GAPMETHOD: NOGAPS, #GAPOPEN:10, GAPEXTEND: 0,5, MATRIX: EBLOSUM62

Table 19:

SEQ 217 218 219 220 221 222

ID NO:

217 100% 95% 95% 93% 90% 90%

218 - 100% 91 % 89% 86% 86%

219 - - 100% 91 % 86% 88%

220 - - - 100% 85% 85%

221 - - - - 100% 83%

222 - - - - - 100%

Preferred combination of features for geneA, geneB, genC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, and geneR. The polypeptides providing the function of geneA, geneB, genC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, and geneR have been described above by a combination of different features 1 to 6 refering to polypeptide and polynucleotide sequences of different degree of identiy to a reference sequence, their capacity to hybridize to a given sequence, or their obtainabilty from the genome of an cornexistin or hydroxycornexistin producing organism. A person having skill in the art will understand that these features can be used individually or in combination to describe the polypeptides providing the respective function.

Accordingly, the polynucleotides and recombinant microorganism may encode or comprise polypeptides being at least 80%, 82%, 84%, 86%, or 88% identical to SEQ ID NO: 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, SEQ ID NO: 154 for genel, SEQ ID NO: 161 for geneJ, SEQ ID NO: 168 for geneK, SEQ ID NO: 175 for geneL, SEQ ID NO: 182 for geneM, SEQ ID NO: 189 for geneN, SEQ ID NO: 196 for geneO, SEQ ID NO: 203 for geneP, SEQ ID NO: 210 for geneQ, and SEQ ID NO: 217 for geneR, respectively.

Preferably they are at least 90%, 91 %, 92%, 93%, or 94%, identical to SEQ ID NO: 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, SEQ ID NO: 154 for genel, SEQ ID NO: 161 for geneJ, SEQ ID NO: 168 for geneK, SEQ ID NO: 175 for genel_, SEQ ID NO: 182 for geneM, SEQ ID NO: 189 for geneN, SEQ ID NO: 196 for geneO, SEQ ID NO: 203 for geneP, SEQ ID NO: 210 for geneQ, and SEQ ID NO: 217 for geneR, respectively.

More preferred they are at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, SEQ ID NO: 154 for genel, SEQ ID NO: 161 for geneJ, SEQ ID NO: 168 for geneK, SEQ ID NO: 175 for genel_, SEQ ID NO: 182 for geneM , SEQ ID NO: 189 for geneN, SEQ ID NO: 196 for geneO, SEQ ID NO: 203 for geneP, SEQ ID NO: 210 for geneQ, and SEQ ID NO: 217 for geneR, respectively.

Even more preferred they are at least 100% identical to SEQ ID NO: 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, SEQ ID NO: 154 for genel, SEQ ID NO: 161 for geneJ, SEQ ID NO: 168 for geneK, SEQ ID NO: 175 for genel_, SEQ ID NO: 182 for geneM, SEQ ID NO: 189 for geneN, SEQ ID NO: 196 for geneO, SEQ ID NO: 203 for geneP, SEQ ID NO: 210 for geneQ, and SEQ ID NO: 217 for geneR, respectively.

Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides being being at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequences listed in Tables 2 to 19 in the description provided above for geneA, geneB, genC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, and geneR, respectively.

Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides which are expressed from polynucleotides which is at least 80%, 82%, 84%, 86% or 88%, identical to SEQ ID NO: 1 , 244 or 14 for geneA, SEQ ID NO: 20, 255, 339 or 32 for geneB, SEQ ID NO: 39, 267 or 51 for geneC, SEQ ID NO: 58, 279 or 70 for geneD, SEQ ID NO: 77, 291 or 89 for geneE, SEQ ID NO: 96, 303 or 108 for geneF, SEQ ID NO: 1 15, 315 or 127forgeneG, SEQ ID NO: 134, 327 or 70 for geneH, SEQ ID NO: 153forgenel, SEQ ID NO: 160forgeneJ, SEQ ID NO: 167forgeneK, SEQ ID NO: 174forgenel_, SEQ ID NO: 181 forgeneM, SEQ ID NO: 188forgeneN, SEQ ID NO: 195forgeneO, SEQ ID NO: 202 forgeneP, SEQ ID NO: 209forgeneQ and SEQ ID NO: 216forgeneR, respectively.

Preferably, they are at least 90%, 91 %, 92%, 93%, or 94%, identical to SEQ ID NO: 1 , 243 or 14 for geneA, SEQ ID NO: 20, 255, 339 or 32 for geneB, SEQ ID NO: 39, 267 or 51 for geneC, SEQ ID NO: 58, 279 or 70 for geneD, SEQ ID NO: 77, 291 or 89 for geneE, SEQ ID NO: 96, 303 or 108forgeneF, SEQ ID NO: 115, 315 or 127forgeneG, SEQ ID NO: 134, 327 or 70 for geneH, SEQ ID NO: 153forgenel, SEQ ID NO: 160forgeneJ, SEQ ID NO: 167forgeneK, SEQ ID NO: 174forgenel_, SEQ ID NO: 181 forgeneM, SEQ ID NO: 188 forgeneN, SEQ ID NO: 195forgeneO, SEQ ID NO: 202 forgeneP, SEQ ID NO: 209 for geneQ and SEQ ID NO: 216 forgeneR, respectively.

More preferred, they are at least 95%, 96% or 97%, identical to SEQ ID NO: 1 , 243 or 14 for geneA, SEQ ID NO: 20, 255, 339 or 32 for geneB, SEQ ID NO: 39, 267 or 51 for geneC, SEQ ID NO: 58, 279 or 70 for geneD, SEQ ID NO: 77, 291 or 89 for geneE, SEQ ID NO: 96, 303 or 108forgeneF, SEQ ID NO: 115, 315 or 127forgeneG, SEQ ID NO: 134, 327 or 70 for geneH, SEQ ID NO: 153forgenel, SEQ ID NO: 160forgeneJ, SEQ ID NO: 167 for geneK, SEQ ID NO: 174forgenel_, SEQ ID NO: 181 forgeneM, SEQ ID NO: 188 for geneN, SEQ ID NO: 195forgeneO, SEQ ID NO: 202 forgeneP, SEQ ID NO: 209 for geneQ and SEQ ID NO: 216 forgeneR, respectively.

Even more preferred, they are at least 98% or 99%, identical to SEQ ID NO: 1 , 243 or 14 for geneA, SEQ ID NO: 20, 255, 339 or 32 for geneB, SEQ ID NO: 39, 267 or 51 for geneC, SEQ ID NO: 58, 279 or 70 for geneD, SEQ ID NO: 77, 291 or 89 for geneE, SEQ ID NO: 96, 303 or 108forgeneF, SEQ ID NO: 115, 315 or 127forgeneG, SEQ ID NO: 134, 327 or 70 for geneH, SEQ ID NO: 153forgenel, SEQ ID NO: 160forgeneJ, SEQ ID NO: 167 for geneK, SEQ ID NO: 174forgenel_, SEQ ID NO: 181 forgeneM, SEQ ID NO: 188 for geneN, SEQ ID NO: 195forgeneO, SEQ ID NO: 202 forgeneP, SEQ ID NO: 209 for geneQ and SEQ ID NO: 216 forgeneR, respectively.

In one embodiment they are 100% identical to SEQ ID NO: 1, 243 or 14 for geneA, SEQ ID NO: 20, 255 or 32 for geneB, SEQ ID NO: 39, 267 or 51 for geneC, SEQ ID NO: 58, 279 or 70 for geneD, SEQ ID NO: 77, 291 or 89 for geneE, SEQ ID NO: 96, 303 or 108forgeneF, SEQ ID NO: 115, 315 or 127forgeneG, SEQ ID NO: 134, 327 or 70 for geneH, SEQ ID NO: 153forgenel, SEQ ID NO: 160forgeneJ, SEQ ID NO: 167 for geneK, SEQ ID NO: 174forgenel_, SEQ ID NO: 181 forgeneM, SEQ ID NO: 188 forgeneN, SEQ ID NO: 195 forgeneO, SEQ ID NO: 202 forgeneP, SEQ ID NO: 209 for geneQ and SEQ ID NO: 216 for geneR, respectively.

Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides which are expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism. Such PCR reactions are preferably primer pairs of at least 15 consecutive polynucleotides per primer, wherein the primer sequences are preferably selected to amplify a polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length sequence of SEQ ID NO: 1 , 243 or 14 for geneA, SEQ ID NO: 20, 255, 339 or 32 for geneB, SEQ ID NO: 39, 267 or 51 for geneC, SEQ ID NO: 58, 279 or 70 for geneD, SEQ ID NO: 77, 291 or 89 for geneE, SEQ ID NO: 96, 303 or 108 for geneF, SEQ ID NO: 1 15, 315 or 127 for geneG, SEQ ID NO: 134, 327 or 70 for geneH, SEQ ID NO: 153 for genel, SEQ ID NO: 160 for geneJ, SEQ ID NO: 167 for geneK, SEQ ID NO: 174 for genel_, SEQ ID NO: 181 for geneM, SEQ ID NO: 188 for geneN, SEQ ID NO: 195 for geneO, SEQ ID NO: 202 for geneP, SEQ ID NO: 209 for geneQ and SEQ ID NO: 216 for geneR, respectively

Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides being at least 60% or 65% identical to 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise at least 80% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Preferably, they are at least 60% or 65% identical to SEQ ID NO: 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise at least 90% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

More Preferred they are at least 60% or 65% identical to 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise at least all of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Even more preferred, they are at least 60% or 65% identical 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise all of the amino acids marked with an black arrow and marked with a black background in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides being at least 70% or 75% identical to 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise at least 80% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Preferably, they are at least 70% or 75% identical to 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise at least 90% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

More Preferred they are at least 70% or 75% identical to 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise at least all of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Even more preferred, they are at least 70% or 75% identical to 2, 244 or 14 for geneA, SEQ ID NO: 21 , 256, 340 or 33 for geneB, SEQ ID NO: 40, 268 or 52 for geneC, SEQ ID NO: 59, 280 or 71 for geneD, SEQ ID NO: 78, 292 or 90 for geneE, SEQ ID NO: 97, 304 or 109 for geneF, SEQ ID NO: 1 16, 316 or 128 for geneG, SEQ ID NO: 135, 328 or 147 for geneH, and comprise all of the amino acids marked with an black arrow and marked with a black background in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides being at least 80% identical to SEQ ID NO: 135 and comprise at least 80% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively. Preferably, they are at least 80% identical to SEQ ID NO: 135 and comprise at least 90% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

More Preferred they are at least 80% identical to SEQ ID NO: 135 and comprise at least all of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Even more preferred, they are at least 80% identical to SEQ ID NO: 135 and comprise at least all of the amino acids marked with an black arrow and marked with a black background in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively. Alternatively, or in combination with other features to describe the respective polypeptides encoded by the polynucleotides or comprised by the recombinant microorganisms, the polynucleotides and recombinant microorganism may encode or comprise polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprise at least 80% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Preferably, they are at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprise at least 90% of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

More Preferred they are at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprise at least all of the amino acids marked with an black arrow in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Even more preferred, they are at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprise at least all of the amino acids marked with an black arrow and marked with a black background in Figure 1 for geneA, Figure 2 for geneB, Figure 3 for geneC, Figure 4 for geneD, Figure 5 for geneE, Figure 6 for geneF, Figure 7 for geneG, Figure 8 for geneH, respectively.

Recombinant polynucleotides:

The present invention provides polynucleotides, which can be used to construct

recombinant microorganisms, in particular recombinant microorganisms which can be used for the production of cornexistin, or hydroxycornexistin, or both and their precursors.

Preferably, the microorganisms used to create the recombinant microorganism, being recombinant for the described polypeptides is already capable to produce cornexistin, cornexistin, or hydroxycornexistin, or both. Usually, the microorganism is transformed to enhance the capacity for production of cornexistin, or hydroxycornexistin, or both, however, in some embodiments the microorganism is transformed to complement a missing gene function in order to provide the microorganism with the capacity to produce cornexistin, or hydroxycornexistin, or both. In some embodiments, the microorganism is transformed in order to destroy or to downregulate its capacity to produce cornexistin, or

hydroxycornexistin, or both. Preferably the microorganism belongs to at least one of the groups of microorganisms defined below under " Recombinant Microorganisms.

Accordingly, the invention comprises polynucleotides selected from the group consisting of: aa) a polynucleotide

aa1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

2, or

aa2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or

aa3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

aa4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 1 , or

aa5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or

aa6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 or

aa7) encoding a polypeptide of at least two of aa1 ), aa2), aa3), aa4), aa5) and aa6); bb) a polynucleotide

bb1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or

bb2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or

bb3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

bb4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 20, or

bb5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or

bb6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) encoding a polypeptide of at least two of bb1 ), bb2), bb3), bb4), bb5) and bb6); a polynucleotide

cc1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or

cc2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or

cc3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

cc4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 39, or

cc5) obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or

hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or

cc6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

cc7) encoding a polypeptide of at least two of cc1 ), cc2), cc3), cc4), cc5) and cc6); a polynucleotide

dd1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or

dd2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or

dd3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

dd4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 58, or

dd5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or

dd6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

dd7) encoding a polypeptide of at least two of dd1 ), dd2), dd3), dd4), dd5) and dd6); ) a polynucleotide

eel ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or

ee2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or

ee3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or

ee4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 77, or

ee5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or

ee6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

ee7) encoding a polypeptide of at least two of eel ), ee2), ee3), ee4), ee5) and ee6); a polynucleotide

ff1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or

ff2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or

ff3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

ff4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 96, or

ff5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or

ff6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

ff7) encoding a polypeptide of at least two of ff1 ), ff2), ff3), ff4), ff5) and ff6);

) a polynucleotide gg1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or

gg2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 ,

122, 123, 124, 125, and/or 126, or

gg3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

gg4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 1 15, or

gg5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or

gg6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

gg7) encoding a polypeptide of at least two of gg1 ), gg2), gg3), gg4), gg5) and gg6); and

hh) a polynucleotide

hh1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

hh2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140,

141 , 142, 143, 144, and/or 145, or

hh3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

hh4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ I D NO: 134, or

hh5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or

hh6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

hh7) encoding a polypeptide of at least two of hh1 ), hh2), hh3), hh4), hh5) and hh6);

It will be understood that the present invention by referring to any of the aforementioned polynucleotides of the invention also refers to complementary or reverse complementary strands of the specific sequences or variants thereof referred to before. The polynucleotide encompasses DNA, including cDNA and genomic DNA, or RNA polynucleotides.

However, the present invention also pertains to polynucleotide variants which are derived from the polynucleotides of the present invention and are capable of interfering with the transcription or translation of the polynucleotides of the present invention. Such variant polynucleotides include anti-sense nucleic acids, ribozymes, siRNA molecules, morpholino nucleic acids (phosphorodiamidate morpholino oligos), triple-helix forming oligonucleotides, inhibitory oligonucleotides, or micro RNA molecules all of which shall specifically recognize the polynucleotide of the invention due to the presence of complementary or substantially complementary sequences. These techniques are well known to the skilled artisan. Suitable variant polynucleotides of the aforementioned kind can be readily designed based on the structure of the polynucleotides of this invention.

Moreover, comprised are also chemically modified polynucleotides including naturally occurring modified polynucleotides such as glycosylated or methylated polynucleotides or artificial modified ones such as biotinylated polynucleotides.

Vectors and Expression Cassettes:

Another embodiment of the invention are vectors comprising any one of the polynucleotides described above.

Preferably, the vector referred to herein is suitable as a cloning vector or transformation vector, i.e. replicable in microbial systems or able to integrate polynucleotides into the genome of a microorganism. Also preferably, the vector of the present invention is an expression vector. Expression vectors comprise expression cassettes which enable the transcription and translation of the polynucleotides in the respective microorganism. The expression cassettes comprise a promoter and a terminator being operably linked to the polynucleotide coding for at least one polypeptide of the invention. The polynucleotides encoding at least one of the polypeptides will preferably be adapted to the codon usage of the respective microorganism. Promoters, terminators and information about codon usage suitable to be used for a particular microorganism are known by a person skilled in the art. Suitable promoters for yeasts or filamentous fungal species are: ADC1 , AOX1 r, GAL1 , MFa , AC, P-60, CYC1 , GAPDH, TEF, rp28, ADH trpC, GAL10, cbhl , hfb2 amyB. Further examples can be taken from Microbiology and Molcular Biology Reviews 70, Pages: 583-ff 2006, or Blumhoff, M et al. " Six novel constitutive promoters for metabolic engineering of Aspergillus niger" (2013) APPLIED MICROBIOLOGY AND BIOTECHNOLOGY Vol. 97 Issue: 1 Pages: 259-267.

The expression cassettes may comprise constitutive or inducible promoters. For example, suitable promoters for yeasts, in particular for Saccharomyces cerevisiae are for example the Gall , Gal 10, Cup1 , Pho5, and Met25 promoters, the trpC, gpdA, tub2 and Tef1 promoters, or the PGM p, ADH1 p, TDH2p, HXT7p, PGK1 p, TEF2p, PYK1 p, EN02p, PDC1 p, FBA1 p, GPDp, GPM 1 p, TPM p, TEF1 p promoters as being disclosed in Sun et al. " Cloning and characterization of a panel of constitutive promoters for applications in pathway engineering in Saccharomyces cerevisiae" (2012); Biotechnology and Bioengineering, Vol. 109, No. 8. Further Promoters and terminators, as well as cloning strategies are described, for example, in Shao et al. (2009) Nucleic Acids Research, Vol. 37, No. 2 e16 (10 pages). One preferred example for a promoter is a promoter described by the nucleic acid sequence of SEQ ID NO: 223. This promoter is preferably used to drive expression in filamentous funge, such as, but not excluding others, Penicillium, Aspergillus, Paecilomyces and Talaromyces. In one embodiment it is used in Paecilomyces divaricatus. Hence, one embodiment of the invention is a recombinant expression cassette comprising a promoter being operatively linked to a polypeptide encoding polynucleotide,

wherein the nucleic acid sequence of the promoter

I) is identical to the nucleic acid sequence as shown in SEQ ID NO: 223 or

II) is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleic acid sequence as shown in SEQ ID NO:

236, or

III) enables the promoter to hybridize under high stringency hybridization conditions to a polynucleotide comprising a nucleic acid sequence as shown in SEQ ID NO: 236, or

IV) is at least 60%, 75% or 80% identical to a nucleic acid sequence as shown in SEQ ID NO: 236 and being obtainable from an expression cassette of a wildtype Paecilomyces divaricatus or Byssochlamys verrucosa genome, wherein the expression cassette comprises a polynucleotide encoding a polypeptide sequence being at least 90%, 95%, or 100% identical to an amino acid sequence as shown in SEQ I D NO: 238, or

V) is at least 60%, 75% or 80% identical to a nucleic acid sequence as shown in SEQ ID NO: 236 and being obtainable from an expression cassette of a wildtype Paecilomyces divaricatus or Byssochlamys verrucosa genome, wherein the expression cassette comprises a polynucleotide having a nucleic acid sequence being at least 90%, 95%, or 100% identical to a nucleic acid sequence as shown in SEQ ID NO: 237, and wherein the operatively linked polypeptide is a

a1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 2, or

a2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or

a3) polynucleotide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 1 , or

a4) polynucleotide which hybridise under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 1 , or

a5) polynucleotide being obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or a6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) polynucleotide comprising at least two of features a1 ), a2), a3), a4), a5) and a6), or b1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%,

90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or

b2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26,

27, 28, 29, 30, and/or 31 , or

b3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

b4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20, or

b5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or

b6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%,

82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) polynucleotide comprising at least two of features b1 ), b2), b3), b4), b5) and b6), or c1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%,

90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or

c2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45,

46, 47, 48, 49, and/or 50, or

c3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

c4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or

c5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or

c6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or c7) polynucleotide comprising at least two of features c1 ), c2), c3), c4), c5) and c6); d1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%,

90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or

d2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64,

65, 66, 67, 68, and/or 69, or

d3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

d4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58, or

d5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or

d6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%,

82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) polynucleotide comprising at least two of features d1 ), d2), d3), d4), d5) and d6), or e1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%,

90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or

e2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83,

84, 85, 86, 87, and/or 88, or

e3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or

e4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77, or

e5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or

e6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%,

82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) polynucleotide comprising at least two of features e1 ), e2), e3), e4), e5) and e6), or f1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%,

90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or

f2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 ,

102, 103, 104, 105, 106, and/or 107, or

f3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

f4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or

f5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or

f6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%,

82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) polynucleotide comprising at least two of features f1), f2), f3), f4), f5) and f6), or g1 ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or

g2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19,

120, 121 , 122, 123, 124, 125, and/or 126, or

g3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

g4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15, or

g5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or

g6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%,

82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) polynucleotide comprising at least two of features g1), g2), g3), g4), g5) and g6), or hi ) polynucleotide encoding a polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) polynucleotide encoding a polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or h3) polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

h4) polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or

h5) polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or

h6) polynucleotide encoding a polypeptide being at least 60%, 65%, 70%, 75%, 80%,

82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) polynucleotide comprising at least two of features h i ), h2), h3), h4), h5) and h6).

The expression cassettes provided herein can be used in combination with expression vectors. A plurality of suitable expression vectors for different microorganisms are known in the art. These vectors are, for example, in E. col), pLG338, pACYC184, the pBR series such as pBR322, the pUC series such as pUC18 or pUC19, the M 1 13mp series, pKC30, pRep4, pHS1 , pHS2, pPLc236, pMBL24, pLG200, pUR290, plN-1111 13-B1 , Iambda-gt1 1 or pBdCI, in Streptomyces plJ 101 , plJ364, plJ702 or plJ361 , in Bacillus pUB1 10, pC194 or pBD214. Examples of vectors for expression in the yeast S. cerevisiae comprise pYep Sec1 (Baldari 1987, Embo J. 6:229-234), pMFa (Kurjan 1982, Cell 30:933-943), pJRY88 (Schultz 1987, Gene 54: 1 13-123) and pYES2 (Invitrogen Corporation, San Diego, CA). Further suitable yeast vectors are, for example, pAG-1 , YEp6, YEp13 or pEMBLYe23. Vectors and processes for the construction of vectors which are suitable for use in other fungi, such as the filamentous fungi, comprise those which are described in detail in: van den Hondel, C.A.M.J.J., & Punt, P.J. (1991 )" Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of fungi, J.F. Peberdy et al., Ed., pp. 1 -28, Cambridge University Press: Cambridge, or in: More Gene Manipulations in Fungi (J.W. Bennett & L.L. Lasure, Ed., pp. 396-428: Academic Press: San Diego).

The present invention also relates to a method for the production of a polypeptide encoded by a polynucleotide of the present invention comprising

a) cultivating the recombinant microorganism of the present invention under conditions which allow for the production of said polypeptide; and

b) obtaining the polypeptide from the recombinant microorganism of step a),

wherein the polypeptide is a

a1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or

a2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or a3) polypeptides expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

a4) polypeptide expressed from a polynucleotide which hybridises under medium

stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or

a5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or a6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

a7) polypeptide comprising at least two of features a1 ), a2), a3), a4), a5) and a6), or b1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or

b2) polypeptides being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or b3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 20, or

b4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20, or

b5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or

b6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) polypeptide comprising at least two of features b1 ), b2), b3), b4), b5) and b6, or c1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or

c2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or c3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

c4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or c5) polypeptides expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO:

39 per primer, or

c6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

c7) polypeptide comprising at least two of features c1 ), c2), c3), c4), c5) and c6), or d1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or

d2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or d3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 58, or

d4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58, or

d5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or

d6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

d7) polypeptide comprising at least two of features d1 ), d2), d3), d4), d5) and d6), or e1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or

e2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or e3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to

SEQ ID NO: 77, or

e4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77, or

e5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or e6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) polypeptide comprising at least two of features e1 ), e2), e3), e4), e5) and e6), or f1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%,

95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or

f2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or

107, or

f3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

f4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or

f5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or

f6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) polypeptide comprising at least two of features f1), f2), f3), f4), f5) and f6), or g1 ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or

g2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, and/or 126, or

g3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

g4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15, or g5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or

g6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) polypeptide comprising at least two of features g1 ), g2), g3), g4), g5) and g6), or hi ) polypeptide being at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) polypeptide being at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or

h3) polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

h4) polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or h5) polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or

h6) polypeptide being at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:

h7) polypeptide comprising at least two of features hi ), h2), h3), h4), h5) and h6). Suitable conditions which allow for expression of the polynucleotide of the invention depend on the recombinant microorganism as well as the expression control sequence used for governing expression of the polynucleotide. These conditions and how to select them are well known to those skilled in the art. The expressed polypeptide may be obtained, for example, by all conventional purification techniques including affinity chromatography, size exclusion chromatography, high pressure liquid chromatography (HPLC) and precipitation techniques including antibody precipitation. It is to be understood that the method may - although preferred -not necessarily yield an essentially pure preparation of the polypeptide. It is to be understood that depending on the recombinant microorganism which is used for the aforementioned method, the polypeptides produced thereby may become

posttranslationally modified or processed otherwise.

Another group of embodiments of the invention are the polypeptide encoded by a

polynucleotide of the present invention or a polypeptide which is obtainable by the aforementioned method of the present invention.

Recombinant Microorganisms:

The polynucleotides and vectors of the present invention are particularly suitable for the production of cornexistin and/or hydroxycornexistin in microorganisms, which comprise at least one of the polynucleotides described above in addition to their natural set of genes or polynucleotides. Preferably the polypeptide encoding polynucleotides will be codon optimized for the respective microorganism. Accordingly, further embodiments of the invention are recombinant microorganisms comprising at least one of the polynucleotides of the invention. This additional

polynucleotide can be comprised by a vector or can be integrated in the genome of the microorganism. Such microorganisms can, for example, be used in processes to produce cornexistin and/or hydrocycornexistin.

Preferably, said recombinant microorganism is a bacterium, an actinomycete, a yeast, a fungus, such as an ascomycete, a deuteromycete, or a basidiomycete, preferably the recombinant microorganism is a bacterial cell, a fungi cell or a yeast cell.

Preferred bacteria to be used as recombinant microorganisms of the present invention are selected from the group consisting of: Escherichia coli and Bacilus subtilis.

Preferred fungi are selected from the group consisting of: the genus Paecilomyces, the genus Byssochlamys, the genus Thermoascus, the genus Monascus, the genus

Aspergillus, the genus Talaromyces and the genus Penicillium. In particular preferred are fungi of the species: Paecilomyces divaricatus, Paecilomyces variotii, Byssochlamys nivea, Byssochlamys verrucosa, Thermoascus aurantiacus, Penicillium chrysogenum, Aspergillus japonicus, Aspergillus niger, Aspergillus nidulans, Aspergillus fumigatus, Aspergillus oryzae and Talaromyces stiptiatus and Talaromyces thermophilus.

Preferred fungi strains are: Byssochlamys verrucosa CBS 605.74, Paecilomyces divaricatus CBS 284.48, Paecilomyces divaricatus CBS 1 10429, Paecilomyces variotii Bainier SANK 21086, Thermoascus crustaceus CBS 117.66, Thermoascus thermophilus CBS 624.74, Aspergillus nidulans ATCC 1 1414 or Aspergillus fumigatus ATCC 46645, Aspergillus niger ATCC 10864 and Penicillium chrysogenum ATCC 1 1500, Aspergillus oryzae ATCC 1015, Aspergillus oryzae ATCC 42149, Talaromyces stipitatus ATCC 10500 and Talaromyces thermophilus ATCC 16461.

Preferred yeasts are seleced from the group consisting of: the genus Saccharomyces, the genus Ashbya, the genus Schizosaccharomyces, the genus Candida and the genus Pichia. In one embodiment the yeast is Saccharomyces cerevisiae.

In one a further embodiment, the recombinant microorganism is of the species

Paecilomyces divaricatus, preferably selected from the group of strains of: Paecilomyces divaricatus CBS 284.48, Paecilomyces divaricatus CBS 1 10429, Paecilomyces variotii Bainier SANK 21086 The polynucleotides isolated from Talaromyces stipitatus and variants thereof can be used to produce recombinant microorganisms comprising such polynucleotides. The

polynucleotides are preferably comprised by expression cassettes which enable the recombinant microorganism to express the encoded polypeptides, for example to provide the recombinant microorganisms with at least one gene providing the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, or to provide the recombinant microorganism with an additional gene for the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, in case the microorganism has already an endogenous gene for the respective function of geneA, geneB, geneC, geneD, geneE, geneF, geneG, or geneH.

Accordingly, the invention includes recombinant microorganisms comprising at least one of a) to h):

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or

a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

b) at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or

b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

b4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20, or b5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or

b6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

d4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58, or d5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or

d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77, or e5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or

e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

at least one expression cassette encoding

f1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104,

105, 106, and/or 107, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or f5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 96 per primer, or

f6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) a polypeptide of at least two of f 1 ), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122,

123, 124, 125, and/or 126, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15, or g5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 1 15 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 ,

142, 143, 144, and/or 145, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or h5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 134 per primer, or

h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

wherein at least one of the expression cassettes of a) to h) is a recombinant expression cassette, or

wherein at least one of the expression cassettes a) to h) is comprised by a recombinant polynucleotide. In some embodiments the recombinant microorganism comprises at least one expression cassette for a), at least one expression cassette for b), at least one expression cassette for c), at least one expression cassette for d), at least one expression cassette for e), at least one expression cassette for f), at least one expression cassette for g) and at least one expression cassette for h).

Preferably, the recombinant microorganism is recombinant for

a) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

b) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

c) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

d) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

e) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 77, or

f) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

g) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

h) at least one expression cassette comprising a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134.

The respective expression cassette is usually suited to enable the recombinant microorganism to express the encoded polypeptides. However, the expression cassette can also be designed to enable the expression in other microorganisms, e.g. in case the recombinant microorganism is a bacterium used to clone expression cassettes for the expression in filamentous fungi.

Preferably, the recombinant microorganism is capable to produce cornexistin or

hydroxycornexistin or both. A preferred microorganism is Paecillomyces divaricatus.

However, the polynucleotides isolated from Talaromyces stipitatus and variants thereof can also be used to complement a microorganism lacking a particular gene for the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, in order to allow the production of cornexistin or hydroxycornexistin or both in such microorganism.

Nevertheless, it is also possible to provide a microorganism which comprises at least one of the polynucleotides isolated from Talaromyces stipitatus and variants thereof encoding polypeptides for the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH, such as, but not excluding others, Talaromyces stipitatus, with a polynucleotide encoding a polypeptide for the function of at least one of geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH. Preferably such polynucleotide is a polynucleotide isolated from Paecilomyces divaricatus and variants thereof encoding polypeptides for such function. In particular at least one, preferably all of the functions of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, geneR.

Thus, the invention comprises recombinant microorganisms, comprising at least one expression cassette for the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG and geneH, and comprising expression cassettes for at least two, three, four, five, six, seven, eight, nine or all of the functions of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ and geneR, wherein at least one of the expression cassettes is a recombinant expression cassette, or wherein at least one of the expression cassettes is comprised by a recombinant polynucleotide. For example, but not excluding other combinations, comprising expression cassettes for at least the functions of geneK and geneL, or geneN and geneP, or geneK and geneQ, or comprising expression cassettes for at least the functions of geneK, geneL, geneN, geneP, and geneQ, or comprising expression cassettes for at least the functions of of genel, geneJ, geneK, geneL, geneN, geneP, and geneQ, or

comprising expression cassettes for at least the functions of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ and geneR.

Accordingly, the invention comprises recombinant microorganisms, comprising a), b), c), d), e), f), g), h) and comprising at least three, four, five, six, seven, eight, nine or all of i), j), k), I), m), n), o), p), q) and r), wherein

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 or 14, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14, 15, 16, 17, 18 and/or 19

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 or 13, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 or 13, or a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 13 per primer, or a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 or 33, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33, 34, 35, 36, 37, and/or 38, or b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20 or 32, or

b4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20 or 32, or b5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 32 per primer, or b6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 or 52, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52, 53, 54, 55, 56, and/or 57, or c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39 or 51 , or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39 or 51 , or c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 51 per primer, or c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 or 71 , or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71 , 72, 73, 74, 75, and/or 76, or d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58 or 70, or

d4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58 or 70, or d5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 70 per primer, or d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 or 90, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90, 91 , 92, 93, 94, and/or 95, or e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77 or 89, or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77 or 89, or e5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 89 per primer, or e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 or 109, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, 1 10, 1 1 1 , 1 12, 1 13, and/or 1 14, or

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96 or 108, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96 or 108, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 108 per primer, or

f7) a polypeptide of at least two of f1 ), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 or 128, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, and/or 126, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, 129, 130, 131 , 132, and/or 133

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 1 15 or 127, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15 or 127, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 127 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 or 147, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147, 148, 149, 150, 151 , and/or 152, or

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134 or 146, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134 or 146, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 146 per primer, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

is at least one expression cassette encoding

11 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 154, or

12) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 154, 155, 156, 157, 158, and/or 159, or

13) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153, or

14) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 153, or

15) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 153 per primer, or

16) a polypeptide of at least two of i 1 ), i2), i3), i4), and i5);

is at least one expression cassette encoding

j1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 161 , or

j2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 161 , 162, 163, 164, 165, and/or 166, or

j3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 160, or

j4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 160, or j5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 160 per primer, or

j6) a polypeptide of at least two of j 1 ), j2), j3), j4), and j5);

is at least one expression cassette encoding

k1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 168, or

k2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 168, 169, 170, 171 , 172, and/or 173, or

k3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 167, or

k4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 167, or k5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 167 per primer, or

k6) a polypeptide of at least two of k1 ), k2), k3), k4), and k5);

is at least one expression cassette encoding

11 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 175, or

12) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 175, 176, 177, 178, 179, and/or 180, or

13) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 174, or

14) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 174, or

15) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 174 per primer, or

16) a polypeptide of at least two of 11 ), I2), I3), I4), and I5);

is at least one expression cassette encoding

ml ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 182, or

m2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 182, 183, 184, 185, 186, and/or 187, or

m3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or

m4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 181 , or m5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 181 per primer, or

m6) a polypeptide of at least two of ml ), m2), m3), m4), and m5);

is at least one expression cassette encoding

n1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 189, or

n2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 189, 190, 191 , 192, 193, and/or 194, or

n3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 188, or n4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 188, or n5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 188 per primer, or

n6) a polypeptide of at least two of n1 ), n2), n3), n4), and n5);

is at least one expression cassette encoding

01 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 196, or

02) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 196, 197, 198, 199, 200, and/or 201 , or

03) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 195, or

04) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 195, or

05) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 195 per primer, or

06) a polypeptide of at least two of o1 ), o2), o3), o4), and o5);

is at least one expression cassette encoding

p1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203, or

p2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203, 204, 205, 206, 207, and/or 208, or

p3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202, or

p4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 202, or p5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 202 per primer, or

p6) a polypeptide of at least two of p1), p2), p3), p4), and p5);

is at least one expression cassette encoding q1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, or

q2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, 21 1 , 212, 213, 214, and/or 215, or

q3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 209, or

q4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 209, or q5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 209 per primer, or

q6) a polypeptide of at least two of q 1 ), q2), q3), q4), and q5);

r) is at least one expression cassette encoding

r1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, or

r2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, 218, 219, 220, 221 , and/or 222, or

r3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 216, or

r4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 216, or r5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 216 per primer, or

r6) a polypeptide of at least two of r1), r2), r3), r4), and r5);

wherein at least one of the expression cassettes of a) to h) is

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26,

27, 28, 29, 30, and/or 31 , or

b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

b4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 20, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 39, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64,

65, 66, 67, 68, and/or 69, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

d4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 58, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or

d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83,

84, 85, 86, 87, and/or 88, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 77, or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 ,

102, 103, 104, 105, 106, and/or 107, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 96, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19,

120, 121 , 122, 123, 124, 125, and/or 126, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 1 15, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138,

139, 140, 141 , 142, 143, 144, and/or 145, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 134, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6); and wherein at least one of the expression cassettes of a) to r) is a recombinant expression cassette, or wherein at least one of the expression cassettes a) to r) is comprised by a recombinant polynucleotide. In one embodiment of the invention, the microorganism comprises at least one expression cassette to provide the function of geneA, at least one expression cassette to provide the function of gene B, at least one expression cassette to provide the function of geneC, at least one expression cassette to provide the function of geneD, at least one expression cassette to provide the function of geneE, at least one expression cassette to provide the function of geneF, at least one expression cassette to provide the function of gene G, at least one expression cassette comprises a polynucleotide encoding a polypeptide to provide the function of geneH, which can be isolated from Talaromyces stipitatus or is a variant of such a polynucleotide encoding a polypeptide capable to provide the same function.

Hence, the invention comprises a recombinant microorganism comprising at least one expression cassette for a), at least one expression cassette b), at least one expression cassette c), at least one expression cassette d), at least one expression cassette e), at least one expression cassette f), at least one expression cassette g) and at least one expression cassette h), wherein

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or

12, or

a7) a polypeptide of at least two of a 1 ), a2), a3), a4), a5) and a6);

b) is at least one expression cassette encoding

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or f5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or

f7) a polypeptide of at least two of f1 ), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

123, 124, 125, and/or 126, or

ID NO: 1 15 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or h5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

Preferably, the expression cassettes used to provide for the function of the respective geneA, geneB, geneC, geneD, geneE, geneF, geneG or geneH in the recombinant microorganisms, comprise

a) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

b) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or

c) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or

d) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or

e) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or

f) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or

g) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or h) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134.

Preferably, the expression cassettes used to provide for the function of the respective genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, geneR in the recombinant microorganisms, comprise

i) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153, or j) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 160, or k) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 167, or

I) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 174, or m) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or n) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 188, or o) a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 195, or

p) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202, or q) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 209, or r) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 216.

The recombinant microorganisms do preferably belong to they belong to the groups of microorganisms described above, even more preferred, they belong to the genus

Aspergillus, Penicillium, Paecillomyces, Bysoclammys, and Talaromyces. Most preferred, they belong to the genus Paecillomyces, in particular to the species Paecillomyces divaricatus.

Preferable, these microorganisms are capable to produce cornexistin or hydroxycornexistin or both.

Methods to enhance the capacity of cornexistin and/or hydroxycornexistin production:

Another part of the invention is a process to produce a recombinant microorganism comprising the steps of: a) transforming a microorganism with a polynucleotide being able to provide the function of at least one of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH or a vector comprising such a polynucleotide; and b) selecting a

microorganism comprising said polynucleotide or said vector.

Polynucleotides which are capable to provide the function of at least one of genes geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH and vectors comprising such polynucleotides have been described above. Polynucleotides comprising at least one of the expression cassettes described above are particularlry suited for the purpose.

The produced recombinant microorganisms can be tested for the production of cornexistin or hydroxycornexistin or the production of cornexistin and hydroxycornexistin, by culturing the recombinant microorganism under conditions which allow for the production of cornexistin or hydroxycornexistin or the production of cornexistin and hydroxycornexistin and analysing the recombinant microorganism or the culture medium or analysing the recombinant microorganism and the culture medium for the presence of cornexistin or hydroxycornexistin or the presence of cornexistin and hydroxycornexistin.

Methods to test for the presence of cornexistin or hydroxycornexistin are known in the art. Examples for such methods are disclosed in US4897104, US4990178 and US5424278.

Processes for the production of cornexistin and/or hydroxycornexistin:

The recombinant polynucleotides, polypeptides, expression cassettes and vectors can be used to produce a recombinant microorganism capable to produce cornexistin,

hydroxycornexistin or both. These microorganism can be used in methods and processes for the production of cornexistin, hycroxycornexistin or both.

Thus, a further part of the invention is a process to produce a recombinant microorganism for the production of cornexistin or hydroxycornexistin or the production of cornexistin and hydroxycornexistin comprising the steps of:

a) transforming a microorganism with at least one polynucleotide capable to provide the function of at least one of genes geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH,

b) selecting a microorganism comprising at least one of the polynucleotides

c) selecting a recombinant microorganism of step

d) producing cornexistin or hydroxycornexistin or both

wherein the recombinant microorganism comprises at least one polypeptide isolated from Talaromyces stipitatus and variants thereof which have been described above to be suited to provide the function of of at least one of genes geneA, geneB, geneC, geneD, geneE, geneF, geneG and geneH. The present invention provides also for a process for the production of cornexistin or hydroxycornexistin or both comprising the steps of:

a) cultivating the recombinant microorganism comprising at least one polynucleotide capable to provide the function of at least one of genes geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH under conditions which allow for the production of cornexistin or hydroxycornexistin or cornexistin and hydroxycornexistin by said recombinant

microorganism; and

b) obtaining produced cornexistin or produced hydroxycornexistin or obtaining produced cornexistin and hydroxycornexistin. Preferably cornexistin or hydroxycornexistin or cornexistin and hydroxycornexistin are obtained from the culture broth,

wherein the recombinant microorganism comprises at least one polypeptide isolated from Talaromyces stipitatus and variants thereof which have been described above to be suited to provide the function of of at least one of genes geneA, geneB, geneC, geneD, geneE, geneF, geneG and geneH. A further process for the production of cornexistin or hydroxycornexistin or the production of cornexistin and hydroxycornexistin comprises the steps of:

a) cultivating a recombinant microorganism of any one of claimsl to 1 1 under conditions which allow for the production of cornexistin or hydroxycornexistin or which allow for the production of cornexistin and hydroxycornexistin by said recombinant microorganism; and

b) obtaining produced cornexistin or produced hydroxycornexistin or obtaining produced cornexistin and hydroxycornexistin,

wherein the recombinant microorganism comprises at least one polypeptide isolated from Talaromyces stipitatus and variants thereof which have been described above to be suited to provide the function of of at least one of genes geneA, geneB, geneC, geneD, geneE, geneF, geneG and geneH.

Preferably the microorganism used to produce the recombinant microorganism to be used in these processes has already the capacity to produce cornexistin, hydroxycornexistin or both. Preferably the recombinant microorganism used in these processes

comprises at least one polynucleotide which is capable to provide the function for geneA, comprises at least one polynucleotide wich is capable to provide the function for geneB, comprises at least one polynucleotide wich is capable to provide the function for geneC, comprises at least one polynucleotide wich is capable to provide the function for geneD, comprises at least one polynucleotide wich is capable to provide the function for geneE, comprises at least one polynucleotide wich is capable to provide the function for geneF, comprises at least one polynucleotide wich is capable to provide the function for geneG, comprises at least one polynucleotide wich is capable to provide the function for geneH, comprises at least one polynucleotide wich is capable to provide the function for genel, comprises at least one polynucleotide wich is capable to provide the function for geneJ, comprises at least one polynucleotide wich is capable to provide the function for geneK, comprises at least one polynucleotide wich is capable to provide the function for geneL, comprises at least one polynucleotide wich is capable to provide the function for geneN, comprises at least one polynucleotide wich is capable to provide the function for geneO, comprises at least one polynucleotide wich is capable to provide the function for geneP, comprises at least one polynucleotide wich is capable to provide the function for geneQ,

Preferably the recombinant microorganism used in these processes

comprises at least one polynucleotide which is capable to provide the function for geneA, comprises at least one polynucleotide wich is capable to provide the function for geneB, comprises at least one polynucleotide wich is capable to provide the function for geneC, comprises at least one polynucleotide wich is capable to provide the function for geneD, comprises at least one polynucleotide wich is capable to provide the function for geneE, comprises at least one polynucleotide wich is capable to provide the function for geneF, comprises at least one polynucleotide wich is capable to provide the function for geneG, comprises at least one polynucleotide wich is capable to provide the function for geneH, comprises at least one polynucleotide wich is capable to provide the function for genel, comprises at least one polynucleotide wich is capable to provide the function for geneJ, comprises at least one polynucleotide wich is capable to provide the function for geneK, comprises at least one polynucleotide wich is capable to provide the function for geneL, comprises at least one polynucleotide wich is capable to provide the function for geneM, comprises at least one polynucleotide wich is capable to provide the function for geneN, comprises at least one polynucleotide wich is capable to provide the function for geneO, comprises at least one polynucleotide wich is capable to provide the function for geneP, comprises at least one polynucleotide wich is capable to provide the function for geneQ, comprises at least one polynucleotide wich is capable to provide the function for geneR.

The microorganism is preferably selected from the groups of microroganisms described above under " Recombinant Microorganisms" . In particular preferred microorganisms are microorganisms which have the capacity to produce cornexistin or hydroxycornexistin or both, for example Paecilomyces divaricatus.

The polynucleotide usually encodes a polypeptide being capable to provide the function of the respective geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ, geneR and is preferably comprised by an expression cassette suited for expression in the respective microorganism. Such polynucleotides, polypeptides and expression cassettes have been described above under the description of the respective headings "Polynucleotides and polypeptides providing geneA function", "Recombinant polynucleotides" and "Vectors and Expression Cassettes".

One embodiment of the invention comprises the processes for the production of cornexistin or hydroxycornexistin as described above, wherein the recombinant microorganism comprises the function of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH, and comprises at least three, four, five, six, seven, eight, nine or all of genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ and geneR, wherein at least one of the expression cassettes for a function of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ or geneR is a recombinant expression cassette, or wherein at least one of the expression cassettes for a function of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ or geneR is comprised by a recombinant polynucleotide.

Preferably, the recombinant microorganism comprises expression cassettes for all of the functions of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH, genel, geneJ, geneK, geneL, geneM, geneN, geneO, geneP, geneQ and geneR.

The microorganism may therefore be described to be a recombinant microorganisms, comprising a), b), c), d), e), f), g), h) and comprising at least three, four, five, six, seven, eight, nine or all of i), j), k), I), m), n), o), p), q) and r), wherein

a) is at least one expression cassette encoding a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 or 14, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

is at least one expression cassette encoding

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

f7) a polypeptide of at least two of f1 ), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15 or 127, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 127 per primer, or g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

is at least one expression cassette encoding

13) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153, or 14) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 153, or

16) a polypeptide of at least two of i 1 ) , i2), i3), i4), and i5);

is at least one expression cassette encoding

j6) a polypeptide of at least two of j 1 ) , j2), j3), j4), and j5);

is at least one expression cassette encoding

k6) a polypeptide of at least two of k1 ), k2), k3), k4), and k5);

is at least one expression cassette encoding 11 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 175, or

16) a polypeptide of at least two of 11 ), I2), I3), I4), and I5);

is at least one expression cassette encoding

m6) a polypeptide of at least two of ml), m2), m3), m4), and m5);

is at least one expression cassette encoding

n3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 188, or

n4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 188, or n5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 188 per primer, or

n6) a polypeptide of at least two of n 1 ), n2), n3), n4), and n5);

is at least one expression cassette encoding

06) a polypeptide of at least two of o1 ), o2), o3), o4), and o5);

is at least one expression cassette encoding

p6) a polypeptide of at least two of p1 ), p2), p3), p4), and p5); q) is at least one expression cassette encoding

q1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, or

q2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 210, 21 1 , 212, 213, 214, and/or 215, or

q3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 209, or

ID NO: 209 per primer, or

q6) a polypeptide of at least two of q 1 ), q2), q3), q4), and q5);

r) is at least one expression cassette encoding

r1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, or

r4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 216, or r5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 216 per primer, or

r6) a polypeptide of at least two of r1), r2), r3), r4), and r5);

wherein at least one of the expression cassettes of a) to h) is

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

12, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 1 per primer, or

a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

at least one expression cassette encoding

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104,

105, 106, and/or 107, or

ID NO: 96 per primer, or

f6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) a polypeptide of at least two of f1 ), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

123, 124, 125, and/or 126, or

ID NO: 1 15 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

h) at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 ,

142, 143, 144, and/or 145, or

ID NO: 134 per primer, or

h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

and wherein at least one of the expression cassettes of a) to r) is a recombinant expression cassette, or wherein at least one of the expression cassettes a) to r) is comprised by a recombinant polynucleotide.

The polynucleotides, polypeptides and expression cassettes having been described above under the description of the respective headings "Polynucleotides and polypeptides providing geneA function", "Recombinant polynucleotides" and "Vectors and Expression

Cassettes"can also be used to enhance the capacity to produce cornexistin or

hydroxycornexistin or both in a microorganism which can already produce cornexistin or hydroxycornexistin or both.

Accordingly, the invention encompasses a method to enhance the production of cornexistin or hydroxycornexistin in an cornexistin or hydroxycornexistin producing microorganism comprising the steps of: providing cells of a microorganism capable to produce cornexistin or hydroxycornexistin,

transforming said cells with at least one of a) to h), wherein,

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 1 , or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

b) is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26,

27, 28, 29, 30, and/or 31 , or

b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 20, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or b6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45,

46, 47, 48, 49, and/or 50, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 39, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64,

65, 66, 67, 68, and/or 69, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 58, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83,

84, 85, 86, 87, and/or 88, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 77, or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 ,

102, 103, 104, 105, 106, and/or 107, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 96, or f5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19,

120, 121 , 122, 123, 124, 125, and/or 126, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 1 15, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138,

139, 140, 141 , 142, 143, 144, and/or 145, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

h7) a polypeptide of at least two of hi ), h2), h3), h4), h5) and h6);

III) identifying transformed microorganism comprising at least one expression cassette of least one of a) to h) of step II),

IV) cultivating transformed microorganism cells of step III) under conditions which allow for the production of cornexistin, or hydroxycornexistin, or which allow for the production of cornexistin and hydroxycornexistin by said transformed microorganism.

The produced cornexistin or hydroxycornexistin or the produced cornexistin and

hydroxycornexistin can be obtained directly, or can be converted to their dibasic acid form and obtained as salts, preferably as agriculturally acceptable salts.

Accordingly, the present invention also encompasses a process for the production of the free dibasic acid of cornexistin or of agriculturally acceptable salts of cornexistin, comprising the steps of: a) cultivating the recombinant microorganism comprising at least one polynucleotide of the invention under conditions which allow for the production of

cornexistin, and b) obtaining produced cornexistin and producing the dibasic acid of cornexistin or producing agriculturally acceptable salts of the dibasic acid of cornexistin. Alternatively, a process for the production of the free dibasic acid of cornexistin or of agriculturally acceptable salts of cornexistin, comprises the steps of: a) cultivating the recombinant microorganism comprising at least one polynucleotide of the invention under conditions which allow for the production of cornexistin, b) producing the dibasic acid of cornexistin or producing agriculturally acceptable salts of the dibasic acid of cornexistin and c) obtaining the dibasic acid of cornexistin or obtaining agriculturally acceptable salts of the dibasic acid of cornexistin.

A further embodiment of the invention is a process for the production of the free dibasic acid of hydroxycornexistin or of agriculturally acceptable salts of hydroxycornexistin, comprising the steps of: a) cultivating the recombinant microorganism comprising at least one polynucleotide of the invention under conditions which allow for the production of hydroxycornexistin, and b) obtaining produced hydroxycornexistin and producing the dibasic acid of hydroxycornexistin or producing agriculturally acceptable salts of the dibasic acid of hydroxycornexistin.

Alternatively, process for the production of the free dibasic acid of hydroxycornexistin or of agriculturally acceptable salts of hydroxycornexistin, comprises the steps of: a) cultivating the recombinant microorganism comprising at least one polynucleotide of the invention under conditions which allow for the production of hydroxycornexistin, b) producing the dibasic acid of hydroxycornexistin or producing agriculturally acceptable salts of the dibasic acid of hydroxycornexistin and c) obtaining the dibasic acid of hydroxycornexistin or obtaining agriculturally acceptable salts of the dibasic acid of hydroxycornexistin.

Methods to produce the dibasic acid of cornexistin and agriculturally acceptable salts of cornexistin are known in the art and, for example, disclosed in US4897104 and

US4990178, which are included herein by reference in their entirety.

The term " cultivating" as used herein refers maintaining and growing the recombinant microorganisms under culture conditions which allow the cells to produce cornexistin and/or hydroxycornexistin. This implies that the polynucleotide of the present invention is expressed in the recombinant microorganism so that the polypeptide(s) encoded by the at least one nucleic acid sequence is present in the recombinant microorganism in a biologically active form. Suitable culture conditions for cultivating the recombinant microorganism are described in more detail in the accompanying Examples below and are known in the art. Preferably the culturing conditions are adapted to the preferred culturing condigions of the respective species of the recombinant microorganism. In particular, recombinant microorganisms of the present invention can be cultured using, for example, glucose, sucrose, honey, dextrin, starch, glycerol, molasses, animal or vegetable oils and the like as the carbon source for the culture medium. Potato flakes are preferably added to the growth medium in case the recombinant microorganism uses promoter sequences comprised by SEQ ID NO: 1 to express the polypeptide(s) endcoded by SEQ ID NO: 1 and does not comprise an expression cassette for expression of the polypeptide of SEQ ID NO: 25, or its variants, under control of a heterologous promoter, preferably an constitutive promoter. Furthermore, soybean flour, wheat germ, corn steep liquor, cotton seed waste, meat extract, polypeptone, malt extract, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used for the nitrogen source. The addition of inorganic salts which can produce sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphoric acid (di- potassium hydrogen phosphate and the like), sulfuric acid (magnesium sulfate and the like) and other ions as required is also effective. Furthermore, various vitamins such as thiamine (thiamine hydrochloride and the like), amino acids such as glutamine (sodium glutamate and the like), asparagine (DL-asparagine and the like), trace nutrients such as nucleotides and the like, and selection drugs such as antibiotics and the like can also be added as required. Moreover, organic substances and inorganic substances can be added

appropriately to assist the growth of the microorganism and promote the production of cornexistin and hydroxycornexistin or the precursor thereof. The pH of the culture medium is, for example, of the order of pH 4.5 to pH 8. The culturing can be carried out with a method such as the solid culturing method under aerobic conditions, the concussion culturing method, the air-passing agitation culturing method or the deep aerobic culturing method, but the deep aerobic culturing method is the most suitable. The appropriate temperature for culturing is from 15°C to 40°C, but in many cases growth occurs in the range from 20°C to 30°C. However, the genus Paecilomyces and Byssochlamys comprise mesophilic, thermotolerant and thermophilic species which can be grown at much higher temperatures.

The production of cornexistin and hydroxycornexistin or its precursors differs according to the culture medium and culturing conditions, or the host which is being used, but with any culturing method the accumulation of cornexistin and hydroxycornexistin reaches a maximum generally in from 5 to 20 days. The culturing is stopped when the amount of cornexistin and hydroxycornexistin or its precursor in the culture reaches its highest level and the target material is isolated from the culture and refined for isolating cornexistin and hydroxycornexistin or a precursor thereof from the culture material.

Examples for such conditions which allow for the production of cornexistin and

hydroxycornexistin are disclosed in US4897104, US4990178 and US5424278 which are included herein by reference in their entirety.

The term " obtaining" as used herein encompasses the provision of the cell culture including the recombinant microorganisms and the culture medium as well as the provision of purified or partially purified preparations thereof comprising the cornexistin and hydroxycornexistin or a precursor thereof, preferably, in free form. More details on purification techniques can be found elsewhere herein below. The usual methods of extraction and refinement which are generally used in these circumstances, such as methods of isolation such as solvent extraction, methods involving ion exchange resins, adsorption or partition chromatography, gel filtration, dialysis, precipitation, crystallization and the like can be used either individually or in appropriate combinations. In particular, cornexistin and hydroxycornexistin can be isolated from a cornexistin and

hydroxycornexistin containing medium or lysate using a known method for isolating cornexistin and hydroxycornexistin. Preferably, the process for isolation disclosed by Furuta 1982, Agricultural and Biological Chemistry (1982), 46(7), 1921 -2 is envisaged in accordance with the method of the present invention.

Examples for methods which allow to obtain cornexistin and hydroxycornexistin, their dibasic forms or their agriculturally acceptable salts are disclosed in US4897104,

US4990178 and US5424278 which are included herein by reference in their entirety. Embodiments comprising polynucleotides and polypeptide sequences obtainable from Bipolaris maydis, Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae or related species.

It is clear, that all polynucleotides, vectors, expression cassettes, recombinant

microorganisms, and methods to enhancde the capacity of cornexistin and/or

hydroxycornexistin production having been described above using polynucleotide and polypeptide sequences for the functions of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH which are obtainable from Talaromyces stipitatus, can also be realized by using polynucleotide and polypeptide sequences obtainable from Bipolaris maydis, Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species. These embodiments will also comprise the variants of polynucleotide and polypeptide sequences for the functions of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH which have been described above.

Accordingly, the invention comprises also the following embodiments:

A microorganism, comprising at least one of a) to h):

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250,

251 , 252, 253 and/or 254, or

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 per primer, or

a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) a polypeptide of at least two of a 1 ), a2), a3), a4), a5) and a6);

b) at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

b4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 255 or 339, or expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 339, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or

hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer

b6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 9, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274,

275, 276, 277, and/or 278, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 267 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286,

287, 288, 289, and/or 290, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or

d4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 279, or d5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 279 per primer, or

d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298,

299, 300, 301 , and/or 302, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 , or e5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 291 per primer, or

e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310,

31 1 , 312, 313 and/or 314, or

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 303, or f5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 303 per primer, or

f6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) a polypeptide of at least two of f 1 ), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322,

323, 324, 325, and/or 326, or

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 315, or g5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 315 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

h) at least one expression cassette encoding

M ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 327, or h5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or

h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

wherein at least one of the expression cassettes a) to h) is comprised by a recombinant polynucleotide.

A microorganism as described above being capable to produce cornexistin or

hydroxycornexistin or both.

A microorganism as described above belonging to the species P. divaricatus.

A microorganism as described above comprising at least one expression cassette for a), at least one expression cassette for b), at least one expression cassette for c), at least one expression cassette for d), at least one expression cassette for e), at least one expression cassette for f), at least one expression cassette for g) and at least one expression cassette for h). A microorganism as described above wherein a) at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or b) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

c) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or d) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or e) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or f) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or g) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or h) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327.

A microorganism, comprising a), b), c), d), e), f), g), h) and comprising at least two of i), j), k), I), m), n), o), p), q) and r), wherein

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 or 14, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247,

248, 249, 250, 251 , 252, 253 and/or 254, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14, 15, 16, 17, 18 and/or 19

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243 or 13, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243 or 13, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 perprimer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 13 per primer, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 or 340 or 33, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33, 34, 35, 36, 37, and/or 38, or b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 or 340 or 32, or

b4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 256 or 340 or 32, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 32 per primer, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267 or 52, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52, 53, 54, 55, 56, and/or 57, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267 or 51 , or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267 or 51 , or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 51 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 or 71 , or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, and/or 290, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID

NO: 71 , 72, 73, 74, 75, and/or 76, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279 or 70, or

NO: 279 or 70, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 70 per primer, or

d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 or 90, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 , and/or 302, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90, 91 , 92, 93, 94, and/or 95, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 or 89, or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 or 89, or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 89 per primer, or e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 or 109, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310, 31 1 , 312, 313 and/or 314, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, 1 10, 1 1 1 , 1 12, 1 13, and/or 1 14, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303 or 108, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 303 or 108, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 303 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 108 per primer, or

f6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 or 128, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322, 323, 324, 325, and/or 326, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, 129, 130, 131 , 132, and/or 133

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315 or 127, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 315 or 127, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 127 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 or 147, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147, 148, 149, 150, 151 , and/or 152, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 or 146, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 328 or 146, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 146 per primer, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

is at least one expression cassette encoding

i 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 154, or

\2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 154, 155, 156, 157, 158, and/or 159, or

13) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 153, or

14) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 153, or

15) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ I D NO: 153 per primer, or

16) a polypeptide of at least two of i 1 ), i2), i3), i4), and i5);

is at least one expression cassette encoding

j 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 161 , or

j2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 161 , 162, 163, 164, 165, and/or 166, or

j3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 160, or

j4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D

NO: 160, or

j5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ I D NO: 160 per primer, or

j6) a polypeptide of at least two of j 1 ) , j2), j3), j4), and j5);

is at least one expression cassette encoding

k1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 168, or k2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 168, 169, 170, 171 , 172, and/or 173, or

k3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 167, or

k4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 167, or

k5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 167 per primer, or

k6) a polypeptide of at least two of k1 ), k2), k3), k4), and k5);

is at least one expression cassette encoding

15) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 174 per primer, or

16) a polypeptide of at least two of 11 ), I2), I3), I4), and I5);

is at least one expression cassette encoding

ml ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 182, or

m3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or m4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 181 , or

m5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 181 per primer, or

m6) a polypeptide of at least two of ml ), m2), m3), m4), and m5);

is at least one expression cassette encoding

n1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 189, or

n3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 188, or

n4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 188, or

n5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 188 per primer, or

n6) a polypeptide of at least two of n1 ), n2), n3), n4), and n5);

is at least one expression cassette encoding

05) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 195 per primer, or

o6) a polypeptide of at least two of o1 ), o2), o3), o4), and o5);

is at least one expression cassette encoding

p1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203, or

p3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202, or

p4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 202, or

p5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 202 per primer, or

p6) a polypeptide of at least two of p1 ), p2), p3), p4), and p5);

is at least one expression cassette encoding

q1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, or

q3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 209, or

q4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 209, or

q5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 209 per primer, or

q6) a polypeptide of at least two of q 1 ), q2), q3), q4), and q5);

is at least one expression cassette encoding

r1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, or r2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, 218, 219, 220, 221 , and/or 222, or

r3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 216, or

r4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 216, or

r5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 216 per primer, or

r6) a polypeptide of at least two of r1 ), r2), r3), r4), and r5);

wherein at least one of the expression cassettes of a) to h) is

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 per primer, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

b) at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID

NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283,

284, 285, 286, 287, 288, 289, and/or 290, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or

NO: 279, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or

d7) a polypeptide of at least two of d1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 , and/or 302, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

NO: 291 , or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or

e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) a polypeptide of at least two of e1), e2), e3), e4), e5) and e6);

at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307,

308, 309, 310, 31 1 , 312, 313 and/or 314, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

NO: 303, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 303 per primer, or

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, or g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319,

320, 321 , 322, 323, 324, 325, and/or 326, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

NO: 315, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or

100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

h) at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

NO: 327, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

A microorganism as described above being capable to produce cornexistin or

hydroxycornexistin or both.

A microorganism as described above belonging to the species P. divaricatus.

A microorganism as described above comprising at least one expression cassette for a), at least one expression cassette b), at least one expression cassette c), at least one expression cassette d), at least one expression cassette e), at least one expression cassette f), at least one expression cassette g) and at least one expression cassette h), wherein

a) is at least one expression cassette encoding

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250,

251 , 252, 253 and/or 254, or

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 243 perprimer, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

b) is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262,

263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274,

275, 276, 277, and/or 278, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

c7) a polypeptide of at least two of c1), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286,

287, 288, 289, and/or 290, or

ID NO: 279 per primer, or

d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298,

299, 300, 301 , and/or 302, or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 , or e5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or

e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310,

31 1 , 312, 313 and/or 314, or

ID NO: 303 per primer, or

f6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

f7) a polypeptide of at least two of f1 ), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322,

323, 324, 325, and/or 326, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 315, or g5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334,

335, 336, 337, and/or 338, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 327, or h5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ

ID NO: 327 per primer, or

h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%,

88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

A microorganism as described above, wherein

a) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or b) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

c) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or d) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or e) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or f) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or g) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or h) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327.

A microorganism as described above, wherein

i) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153, or j) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 160, or k) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 167, or

I) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 174, or m) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or n) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 188, or o) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 195, or

p) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202, or q) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 209, or r) is at least one expression cassette encoding a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 216.

A recombinant polynucleotide selected from the group consisting of:

aa) a polynucleotide

aa1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

aa2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or

aa3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

aa4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 243, or

aa5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 perprimer, or

aa6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 or

bb1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or bb2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

bb3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

bb4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 255 or 339, or which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 339, or bb5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer, or

bb6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 9, or

b7) encoding a polypeptide of at least two of bb1 ), bb2), bb3), bb4), bb5) and bb6); cc) a polynucleotide

cc1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

cc2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273,

274, 275, 276, 277, and/or 278, or

cc3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

cc4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 267, or

cc5) obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or

hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

cc6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

cc7) encoding a polypeptide of at least two of cc1 ), cc2), cc3), cc4), cc5) and cc6); dd) a polynucleotide

dd1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or

dd2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, and/or 290, or

dd3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or dd4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 279, or

dd5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or

dd6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

dd7) encoding a polypeptide of at least two of dd 1 ), dd2), dd3), dd4), dd5) and dd6); ee) a polynucleotide

eel ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

ee2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 , and/or 302, or

ee3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

ee4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 291 , or

ee5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or

ee6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

ee7) encoding a polypeptide of at least two of eel ), ee2), ee3), ee4), ee5) and ee6); ff) a polynucleotide

ff1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, or

ff2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309,

310, 31 1 , 312, 313 and/or 314, or

ff3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

ff4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 303, or

ff5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 303 per primer, or ff6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

a polynucleotide

gg1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, or

gg2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 ,

322, 323, 324, 325, and/or 326, or

gg3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

gg4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 315, or

gg5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or

gg6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

a polynucleotide

hh1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, or

hh2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333,

334, 335, 336, 337, and/or 338, or

hh3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

hh4) which hybridises under medium stringency hybridisation conditions, to a

complement of SEQ ID NO: 327, or

hh5) which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or

hh6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%,

86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

hh7) encoding a polypeptide of at least two of hh1 ), hh2), hh3), hh4), hh5) and hh6); A recombinant polynucleotide as described above selected from the group of:

aa) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243,

bb) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 223,

cc) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267,

dd) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58,

ee) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 ,

ff) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96,

gg) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, and hh) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327. A vector comprising a recombinant polynucleotide as described above.

A microorganism comprising a recombinant polynucleotide or a vector as described above.

The recombinant microorganism as described above, wherin said recombinant

microorganism is a bacterium, a fungus or yeast.

A process for the production of cornexistin or hydroxycornexistin or the production of cornexistin and hydroxycornexistin comprising the steps of:

a) cultivating a recombinant microorganism as described above under conditions which allow for the production of cornexistin or hydroxycornexistin or which allow for the production of cornexistin and hydroxycornexistin by said recombinant microorganism; and

b) obtaining produced cornexistin or produced hydroxycornexistin or obtaining produced cornexistin and hydroxycornexistin.

The process as described above, wherein cornexistin or hydroxycornexistin or cornexistin and hydroxycornexistin are obtained from the culture broth. The process as described above, wherein at least one of cornexistin or hydroxycornexistin is obtained as dibasic acid thereof or in the form of its agriculturally acceptable salt. A method to enhance the production of cornexistin or hydroxycornexistin in an cornexistin or hydroxycornexistin producing microorganism comprising the steps of:

I) providing cells of a microorganism capable to produce cornexistin or

hydroxycornexistin,

II) transforming said cells with at least one of a) to h), wherein,

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

248, 249, 250, 251 , 252, 253 and/or 254, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 perprimer, or

a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6); b) is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 ,

272, 273, 274, 275, 276, 277, and/or 278, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

NO: 267, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283,

284, 285, 286, 287, 288, 289, and/or 290, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 279, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295,

296, 297, 298, 299, 300, 301 , and/or 302, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 , or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307,

308, 309, 310, 31 1 , 312, 313 and/or 314, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 303, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%,

97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319,

320, 321 , 322, 323, 324, 325, and/or 326, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 315, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6); h) is at least one expression cassette encoding

h i ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID

NO: 328, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 327, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%,

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6); III) identifying transformed microorganism comprising at least one expression cassette of least one of a) to h) of step II),

The method as described above, wherein the microorganism capable to produce

cornexistin or hydroxycornexistin is Paecilomyces divaricatus The method as described above, wherein at least one of cornexistin or hydroxycornexistin is obtained as dibasic acid thereof or in the form of its agriculturally acceptable salt. Use of at least one of the polynucleotides as described above, or at least one of the vectors as described above, to produce a recombinant microorganism as described above.

Use of at least one of the polynucleotides as described above, or of at least one of the vectors as described above, in a process as described above or in a method as described above.

Use of at least one of the polynucleotides as described above, or at least one of the vectors as described above, or of at least one of the recombinant microorganisms as described above for the manufacture of cornexistin or hydroxycornexistin or for the manufacture of cornexistin and hydroxycornexistin.

All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.

EXAMPLES

Example 1 : Overexpression of the transporter protein 2 from Talaroymces stipitatus in

Paecilomyces divaricatus for the production of Cornexistin and Hydroxycornexistin

In order to increase cornexistin and hydroxycornexistin production the transporter protein 2 (SEQ ID NO: 135, encoded by SEQ ID NO: 134) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Transporter 2 Ts (SEQ ID NO: 227) is constructed using OPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Transporter 2 Ts (SEQ ID NO: 227). (for transformation procedure see US 14/084030 and EP13182735.4). Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and EP13182735.4). PCR is performed using primers Phsp9 fw and

Transporter 2 Ts rv (SEQ IDs NO: 225 and 228) to identify clones with an integrated overexpression construct.

The wild type strain and three transporter 2 overexpression clones are investigated for Cornexistin production by shake flask experiments:

2 ml_ of Paecilomyes divaricatus conidiospore suspension (^~10⁹ spores/mL, either from wild type or from overexpression clones) are grown in 100 ml_ preculture medium (20 g/L glucose-monohydrate, 20 g/L polypeptone, 10 g/L malt extract, 10 g/L yeast extract, 1 g/L K2HPO4, 0.5 g/L MgS0₄ x 7 H₂0, 0.001 % silicon oil AR 1000, pH 7.0) filled in 500 mL Erlenmeyer flasks without baffles. Flasks are incubated for 3 days at 26°C and 220 rpm. 2 mL of the pre culture are used to inoculate 100 mL production medium (50g/L potato flakes, 50 g/L glycerol, 4 g/L urea, pH 6.0) filled in 500 mL Erlenmeyer flasks without baffles. All flasks are incubated for 13 days at 26°C and 220 rpm. The mycelium is harvested and the supernatant is extracted and analyzed for Cornexistin production by HPLC (see US 14/084030 and EP13182735.4). The results show the averaged titer of 2 independent shake flasks per clone.

Table 20 Results of Example 1 :

Example 2: Overexpression of the transporter protein 1 from Talaroymces stipitatus in

In order to increase cornexistin and hydroxycornexistin production the transporter protein 1 (SEQ IDs NO: 1 16, encoded by SEQ ID NO: 1 15) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Transporter 1 Ts (SEQ ID NO: 224) is constructed using OPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Transporter 1 Ts (SEQ ID NO: 224) (for transformation procedure see US14/084030 and EP13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Transporter 1 Ts rv (SEQ IDs NO: 225 and 226) to identify clones with an integrated overexpression construct.

The wild type strain and 3 transporter 1 overexpression clones are investigated for

Cornexistin production by shake flask experiments:

2 mL of Paecilomyes divaricatus conidiospore suspension (^~10⁹ spores/mL, either from wild type or from overexpression clones) are grown in 100 mL preculture medium (20 g/L glucose-monohydrate, 20 g/L polypeptone, 10 g/L malt extract, 10 g/L yeast extract, 1 g/L K2HPO4, 0.5 g/L MgS0₄ x 7 H₂0, 0.001 % silicon oil AR 1000, pH 7.0) filled in 500 mL Erlenmeyer flasks without baffles. Flasks are incubated for 3 days at 26°C and 220 rpm. 2 mL of the pre culture are used to inoculate 100 mL production medium (50g/L potato flakes, 50 g/L glycerol, 4 g/L urea, pH 6.0) filled in 500 mL Erlenmeyer flasks without baffles. All flasks are incubated for 13 days at 26°C and 220 rpm. The mycelium is harvested and the supernatant is extracted and analyzed for Cornexistin production by HPLC (see US 14/084030 and EP13182735.4). The results show the averaged titer of 2 independent shake flasks per clone. Table 21 Results of Example 2:

Example 3: Overexpression of the hypothetical protein from Talaroymces stipitatus in

In order to increase cornexistin and hydroxycornexistin production the hypothetical protein (SEQ IDs NO: 78, encoded by SEQ ID NO: 77) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 225).

For this means the overexpression plasmid pHOFF6 Phsp9-Hypothetical protein Ts (SEQ ID NO: 229) is constructed using OPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Hypothetical protein Ts (SEQ ID NO: 229) (for transformation procedure see US 14/084030 and EP13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Hypothetical protein Ts rv (SEQ IDs NO: 225 and 230) to identify clones with an integrated overexpression construct. The wild type strain and 3 hypothetical protein overexpression clones are investigated for Cornexistin production by shake flask experiments:

2 mL of Paecilomyes divaricatus conidiospore suspension (^~10⁹ spores/mL, either from wild type or from overexpression clones) are grown in 100 mL preculture medium (20 g/L glucose-monohydrate, 20 g/L polypeptone, 10 g/L malt extract, 10 g/L yeast extract, 1 g/L K2HPO4, 0.5 g/L MgS0₄ x 7 H₂0, 0.001 % silicon oil AR 1000, pH 7.0) filled in 500 mL Erlenmeyer flasks without baffles. Flasks are incubated for 3 days at 26°C and 220 rpm. 2 mL of the pre culture are used to inoculate 100 mL production medium (50g/L potato flakes, 50 g/L glycerol, 4 g/L urea, pH 6.0) filled in 500 mL Erlenmeyer flasks without baffles. All flasks are incubated for 13 days at 26°C and 220 rpm. The mycelium is harvested and the supernatant is extracted and analyzed for Cornexistin production by HPLC (see US 14/084030 and EP13182735.4). The results show the averaged titer of 2 independent shake flasks per clone.

Table 22 Results of Example 3:

Example 4: Overexpression of the methylcitrate synthase from Talaroymces stipitatus in

In order to increase cornexistin and hydroxycornexistin production the methylcitrate synthase (SEQ IDs NO: 59, encoded by SEQ ID NO: 58) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Methylcitrate synthase Ts (SEQ ID NO: 231 ) is constructed using OPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Methylcitrate synthase Ts (SEQ ID NO: 231 ) (for transformation procedure see US 14/084030 and EP13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Methylcitrate synthase Ts rv (SEQ IDs NO: 225 and 232) to identify clones with an integrated overexpression construct.

The wild type strain and 2 methylcitrate synthase overexpression clones are investigated for Cornexistin production by shake flask experiments:

Table 23 Results of Example 4:

Example 5: Overexpression of the thioesterase from Talaroymces stipitatus in

In order to increase cornexistin and hydroxycornexistin production the thioesterase (SEQ IDs NO: 97, encoded by SEQ ID NO: 96) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Thioesterase Ts (SEQ ID NO 233) is constructed using CPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Thioesterase Ts (SEQ ID NO: 233) (for transformation procedure see US 14/084030 and EP13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Thioesterase Ts rv (SEQ IDs NO: 225 and 234) to identify clones with an integrated overexpression construct.

The wild type strain and 4 thioesterase overexpression clones are investigated for

Cornexistin production by shake flask experiments:

Table 24 Results of Example 5:

Example 6: Overexpression of the polyketide synthase from Talaroymces stipitatus in Paecilomyces divaricatus for the production of Cornexistin and Hydroxycornexistin

In order to increase cornexistin and hydroxycornexistin production the polyketide synthase (SEQ IDs NO: 2, encoded by SEQ ID NO: 1 ) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Polyketide synthase Ts (SEQ ID NO: 235) is constructed using CPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Polyketide synthase Ts (SEQ ID NO: 235) (for transformation procedure see US 14/084030 and EP13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Polyketide synthase Ts rv (SEQ IDs NO: 225 and 236) to identify clones with an integrated overexpression construct. The wild type strain and 3 polyketide synthase overexpression clones are investigated for Cornexistin production by shake flask experiments:

2 mL of Paecilomyes divaricatus conidiospore suspension (^~10⁹ spores/mL, either from wild type or from overexpression clones) are grown in 100 mL preculture medium (20 g/L glucose-monohydrate, 20 g/L polypeptone, 10 g/L malt extract, 10 g/L yeast extract, 1 g/L K2HPO4, 0.5 g/L MgS0₄ x 7 H₂0, 0.001 % silicon oil AR 1000, pH 7.0) filled in 500 mL Erlenmeyer flasks without baffles. Flasks are incubated for 3 days at 26°C and 220 rpm. 2 mL of the pre culture are used to inoculate 100 mL production medium (50g/L potato flakes, 50 g/L glycerol, 4 g/L urea, pH 6.0) filled in 500 mL Erlenmeyer flasks without baffles. All flasks are incubated for 13 days at 26°C and 220 rpm. The mycelium is harvested and the supernatant is extracted and analyzed for Cornexistin production by HPLC (see US14/084030 and EP13182735.4). The results show the averaged titer of 2 independent shake flasks per clone.

Table 25 Results of Example 6:

Strain Productivity of Cornexistin [mg/L]

SANK 21086 385.15

SANK 21086, Phsp9-PKS Ts clone 11 614.97

SANK 21086, Phsp9-PKS Ts clone 12 625.24

SANK 21086, Phsp9-PKS Ts clone 15 836.59

Example 7: Overexpression of the polyketide cyclase from Talaroymces stipitatus in Paecilomyces divaricatus for the production of Cornexistin and Hydroxycornexistin

In order to increase cornexistin and hydroxycornexistin production the polyketide cyclase (SEQ IDs NO: 21 , encoded by SEQ ID NO: 20) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Polyketide cyclase Ts (SEQ ID NO: 237) is constructed using CPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Polyketide cyclase Ts (SEQ ID NO: 237) (for transformation procedure see

US 14/084030 and EP13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Polyketide cyclase Ts rv (SEQ IDs NO: 225 and 238) to identify clones with an integrated overexpression construct. The wild type strain and 3 polyketide cyclase overexpression clones are investigated for Cornexistin production by shake flask experiments:

Table 26 Results of Example 7:

Example 8: Overexpression of the citrate synthase from Talaroymces stipitatus in

In order to increase Cornexistin and Hydroxycornexistin production the citrate synthase (SEQ IDs NO: 40, endoced by SEQ ID NO: 39) is overexpressed using the strong HSP9 promoter from Paecilomyces divaricatus (SEQ ID NO: 223).

For this means the overexpression plasmid pHOFF6 Phsp9-Citrate synthase Ts (SEQ ID NO: 239) is constructed using CPEC (Circular Polymerase Extension Cloning).

Paecilomyces divaricatus is transformed with the circular overexpression construct pHOFF6 Phsp9-Citrate synthase Ts (SEQ ID NO: 239) for transformation procedure see

US14/084030 and EP 13182735.4).

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and Citrate synthase Ts rv (SEQ IDs NO: 225 and 240) to identify clones with an integrated overexpression construct. The wild type strain and 3 citrate synthase overexpression clones are investigated for Cornexistin production by shake flask experiments:

2 mL of Paecilomyes divaricatus conidiospore suspension (^~10⁹ spores/mL, either from wild type or from overexpression clones) are grown in 100 mL preculture medium (20 g/L glucose-monohydrate, 20 g/L polypeptone, 10 g/L malt extract, 10 g/L yeast extract, 1 g/L K2HPO4, 0.5 g/L MgS0₄ x 7 H₂0, 0.001 % silicon oil AR 1000, pH 7.0) filled in 500 mL Erlenmeyer flasks without baffles. Flasks are incubated for 3 days at 26°C and 220 rpm. 2 mL of the pre culture are used to inoculate 100 mL production medium (50g/L potato flakes, 50 g/L glycerol, 4 g/L urea, pH 6.0) filled in 500 mL Erlenmeyer flasks without baffles. All flasks are incubated for 13 days at 26°C and 220 rpm. The mycelium is harvested and the supernatant is extracted and analyzed for Cornexistin production by HPLC (see US 14/084030 and EP13182735.4). The results show the averaged titer of 2 independent shake flasks per clone. Table 27 Results of Example 8:

Example 9: Control experiment to verify that the increase of Cornexistin and

Hydroxycornexistin production is specifically dependent from the integration and

overexpression of homologous genes from Talaromyces stipitatus in Paecilomyces divaricatus

In order to verify that the increase of cornexistin and hydroxycornexistin production is specifically dependent from the integration and overexpression of homologous genes from Talaromyces stipitatus in Paecilomyces divaricatus, the control plasmid pHOFF6-Phsp9 (SEQ ID NO: 241 ) is transformed (for transformation procedure see US14/084030 and EP13182735.4) and ectopically integrated in the Paecilomyces divaricatus genome. This plasmid contains only the hsp9 promoter and the trpC terminator but no gene of interest between the regulatory sequences.

Genomic DNA is isolated from Hygromycin resistant clones (see US 14/084030 and

EP13182735.4). PCR is performed using primers Phsp9 fw and TtrpC rv (SEQ IDs NO: 225 and 242) to identify clones with the integrated control construct.

The wild type strain and 3 clones which have integrated the control construct pHOFF6- Phsp9 are investigated for Cornexistin production by shake flask experiments:

Table 28 Results of Example 8:

SANK 21086, pHOFF6-Phsp9 clone 6 229,86

SANK 21086, pHOFF6-Phsp9 clone 8 234,2

The Examples 1 to 8 described above using polynucleotide and polypeptide sequences for the functions of geneA, geneB, geneC, geneD, geneE, geneF, geneG, geneH which are obtainable from Talaromyces stipitatus, can also be realized by using polynucleotide and polypeptide sequences obtainable from Bipolaris maydis, Bipolaris victoria, Bipolaris zeicola, Bipolaris oryzae and related species as well as the variants of those polynucleotide and polypeptide sequences.

Claims

A microorganism, comprising at least one of a) to h):

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254 , or a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 per primer, or

a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6); b) at least one expression cassette encoding b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%,

91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or a polypeptide which is at least 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID

NO: 255 or 339, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

NO: 20, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 255 or 339, or expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 339, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of

SEQ ID NO: 339 per primer, or

b6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340 and

comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 3, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, and/or 290, or d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or

d4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 279, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or

d6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 , and/or 302, or e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 , or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or

e6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6); at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310, 31 1 , 312, 313 and/or 314, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 303, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 303 per primer, or

f6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, and/or 126, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322, 323, 324, 325, and/or 326, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 315, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, or h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 327, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

wherein at least one of the expression cassettes a) to h) is comprised by a

recombinant polynucleotide.

A microorganism as claimed in claim 1 , being capable to produce cornexistin or hydroxycornexistin or both.

A microorganism as claimed in claim 1 or 2, belonging to the species P. divaricatus. A microorganism as claimed in any one of claims 1 to 3, comprising at least one expression cassette for a), at least one expression cassette for b), at least one expression cassette for c), at least one expression cassette for d), at least one expression cassette for e), at least one expression cassette for f), at least one expression cassette for g) and at least one expression cassette for h).

A microorganism as claimed in any one of claims 1 to 4, wherein

a) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

b) at least one expression cassette encodies a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or c) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

d) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or

e) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

f) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

g) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

h) at least one expression cassette encodes a polypeptide expressed from a

polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or at least one expression cassette encodes a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327.

A microorganism, comprising a), b), c), d), e), f), g), h) and comprising at least two of i) , j), k), I), m), n), o), p), q) and r), wherein

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 or 14, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 or 14, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14, 15, 16, 17, 18 and/or 19, a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14, 15, 16, 17, 18 and/or 19, or

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 or 13, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243 or 13, or

a4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 or 13, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 243 or 13, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 13 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 perprimer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 13 per primer, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 or 33, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 or 340 or 33, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33, 34, 35, 36, 37, and/or 38, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33, 34, 35, 36, 37, and/or 38, or

a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20 or 32, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 or 340 or 32, or

a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20 or 32, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 256 or 340 or 32, or

a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 32 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 32 per primer, or

a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) a polypeptide of at least two of b1), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 or 52, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267 or 52, or

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52, 53, 54, 55, 56, and/or 57, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52, 53, 54, 55, 56, and/or 57, or

c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39 or 51 , or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267 or 51 , or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39 or 51 , or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267 or 51 , or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 51 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 51 per primer, or

c6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 or 71 , or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 or 71 , or

d2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71 , 72, 73, 74, 75, and/or 76, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, and/or 290, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71 , 72, 73, 74, 75, and/or 76, or

d3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58 or 70, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279 or 70, or

d4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58 or 70, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 279 or 70, or

d5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 70 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 70 per primer, or

d7) a polypeptide of at least two of d1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 or 90, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 or 90, or

e2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, and/or 88, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90, 91 , 92, 93, 94, and/or 95, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, 293, 294, 295, 296, 297, 298, 299, 300, 301 , and/or 302, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90, 91 , 92, 93, 94, and/or 95, or

e3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77 or 89, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 or 89, or

e4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77 or 89, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 or 89, or

e5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 89 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive

polynucleotides of SEQ ID NO: 291 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive

polynucleotides of SEQ ID NO: 89 per primer, or

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 or 109, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 or 109, or

f2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, 1 10, 1 1 1 , 1 12, 1 13, and/or 1 14, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310, 31 1 , 312, 313 and/or 314, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, 1 10, 1 1 1 , 1 12, 1 13, and/or 1 14, or

f3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96 or 108, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303 or 108, or

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96 or 108, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 303 or 108, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 108 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive

polynucleotides of SEQ ID NO: 303 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive

polynucleotides of SEQ ID NO: 108 per primer, or

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 or 128, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 or 128, or

g2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, and/or 126, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, 129, 130, 131 , 132, and/or 133, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322, 323, 324, 325, and/or 326, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, 129, 130, 131 , 132, and/or 133, or

g3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15 or 127, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315 or 127, or

g4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15 or 127, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 315 or 127, or

g5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 127 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 127 per primer, or

g6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 or 147, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 or 147, or

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147, 148, 149, 150, 151 , and/or 152, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147, 148, 149, 150, 151 , and/or 152, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134 or 146, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 or 146, or

h4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134 or 146, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 328 or 146, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 146 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive

polynucleotides of SEQ ID NO: 327 per primer, or which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive

polynucleotides of SEQ ID NO: 146 per primer, or

h7) a polypeptide of at least two of hi), h2), h3), h4), h5) and h6);

is at least one expression cassette encoding

i1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 154, or

15) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ I D NO: 153 per primer, or

16) a polypeptide of at least two of i 1 ), i2), i3), i4), and i5);

is at least one expression cassette encoding

j 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

j3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 160, or

j5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ I D NO: 160 per primer, or

j6) a polypeptide of at least two of j 1 ) , j2), j3), j4), and j5);

is at least one expression cassette encoding

k1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 168, or

k2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 168, 169, 170, 171 , 172, and/or 173, or

k4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 167, or

k5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 167 per primer, or

k6) a polypeptide of at least two of k1 ), k2), k3), k4), and k5);

is at least one expression cassette encoding

15) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 174 per primer, or

16) a polypeptide of at least two of 11 ), I2), I3), I4), and I5);

is at least one expression cassette encoding

ml ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 182, or

m3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or

m4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID

NO: 181 , or

m5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 181 per primer, or

m6) a polypeptide of at least two of ml ), m2), m3), m4), and m5);

is at least one expression cassette encoding

n1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 189, or

n3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 188, or

n5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 188 per primer, or

n6) a polypeptide of at least two of n1), n2), n3), n4), and n5);

is at least one expression cassette encoding

05) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 195 per primer, or

06) a polypeptide of at least two of o1), o2), o3), o4), and o5);

is at least one expression cassette encoding

p3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 202, or

p5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 202 per primer, or

p6) a polypeptide of at least two of p1), p2), p3), p4), and p5);

is at least one expression cassette encoding

q1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 210, or

q3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

NO: 209, or

q5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 209 per primer, or

q6) a polypeptide of at least two of q 1 ), q2), q3), q4), and q5);

is at least one expression cassette encoding

r1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 217, or

r4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 216, or

r5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 216 per primer, or

r6) a polypeptide of at least two of r1 ), r2), r3), r4), and r5);

wherein at least one of the expression cassettes of a) to h) is

a) at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%,

91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or a polypeptide which is at least 90%, 91 %, 92%, 93%,

94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or

a3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

NO: 1 , or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 per primer, or a6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or

b2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

b3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

b4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 255 or 339, or expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 339, or

b5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer, or

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or c5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

d5) a polypeptide expressed from a polynucleotide which is obtainable via

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

e5) a polypeptide expressed from a polynucleotide which is obtainable via

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

f4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

f5) a polypeptide expressed from a polynucleotide which is obtainable via

f7) a polypeptide of at least two of f 1 ), f2), f3), f4), f5) and f6);

at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

g5) a polypeptide expressed from a polynucleotide which is obtainable via

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

h) at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID

NO: 135, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328,

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138,

139, 140, 141 , 142, 143, 144, and/or 145, or or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or

h3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%,

84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6);

A microorganism as claimed in claim 6, being capable to produce cornexistin or hydroxycornexistin or both.

A microorganism as claimed in claim 6 or 7, belonging to the species P. divaricatus.

A microorganism as claimed in any one of claims 6 to 8, comprising at least one expression cassette a), at least one expression cassette b), at least one expression cassette c), at least one expression cassette d), at least one expression cassette e), at least one expression cassette f), at least one expression cassette g) and at least one expression cassette h), wherein

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

a2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or

a5) a polypeptide expressed from a polynucleotide which is obtainable via

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

b5) a polypeptide expressed from a polynucleotide which is obtainable via

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

d5) a polypeptide expressed from a polynucleotide which is obtainable via

d7) a polypeptide of at least two of d1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

e5) a polypeptide expressed from a polynucleotide which is obtainable via

e7) a polypeptide of at least two of e1 ), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

f5) a polypeptide expressed from a polynucleotide which is obtainable via

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

g5) a polypeptide expressed from a polynucleotide which is obtainable via

g7) a polypeptide of at least two of g1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328,

h2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or h7) a polypeptide of at least two of h 1 ), h2), h3), h4), h5) and h6).

A microorganism as claimed in any one of claims 6 to 9, wherein

a) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

b) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

c) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

d) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or

e) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

f) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

g) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

h) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327. 1 1. A microorganism as claimed in any one of claims 6 to 10, wherein

i) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153, or

j) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 160, or

k) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 167, or

I) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 174, or

m) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 181 , or

n) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 188, or

is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ I D NO: 195, or

is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202, or

q) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 209, or

r) is at least one expression cassette encoding a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 216.

A recombinant polynucleotide selected from the group consisting of:

aa) a polynucleotide

aa1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, or

aa2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , and/or 12, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253 and/or 254, or aa3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, or

aa4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 , or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 243, or

aa5) which which is obtainable via PCR on genomic DNA or cDNA of a

pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 per primer, or

aa6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 244 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 1 , or

aa7) which has at least two of features aa1), aa2), aa3), aa4), aa5) and aa6); a polynucleotide

bb1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, or which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, or

bb2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, and/or 31 , or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, and/or 266, or which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340, 341 , 342, 343, 344, 345, 346, 347, 348, 349, and/or 350, or

bb3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 339, or

bb4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 20, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 255 or 339, or expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 339, or bb5) which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 20 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 255 or 339 per primer, or expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 339 per primer, or

bb6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 256 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 340 and comprising at least 80%, 90% or all of the amino acids marked with a black arrow in Figure 2, or

b7) which has at least two of features bb1), bb2), bb3), bb4), bb5) and bb6); a polynucleotide

cc1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, or

cc2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or cc3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or

cc4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or

cc5) which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 39 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 267 per primer, or

cc6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 3, or

cc7) which has at least two of features cc1 ), cc2), cc3), cc4), cc5) and cc6); a polynucleotide

dd1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, or

dd2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, and/or 69, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, and/or 290, or dd3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, or

dd4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 58, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 279, or

dd5) which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 58 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 279 per primer, or

dd6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 280 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 4, or

dd7) which has at least two of features dd1), dd2), dd3), dd4), dd5) and dd6); a polynucleotide

eel ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292, or

ee3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , or

ee4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 77, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 291 , or

ee5) which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 77 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 291 per primer, or

ee6) encoding a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 292 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 5, or

ee7) which has at least two of features eel ), ee2), ee3), ee4), ee5) and ee6); a polynucleotide

ff1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, or

ff2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, and/or 107, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304, 305, 306, 307, 308, 309, 310, 31 1 , 312, 313 and/or 314, or

ff3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

ff4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 96, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303, or

ff5) which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 96 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 303 per primer, or

ff6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 304 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 6, or

ff7) which has at least two of features ff1 ), ff2), ff3), ff4), ff5) and ff6);

a polynucleotide gg1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, or

gg2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16, 1 17, 1 18, 1 19, 120, 121 , 122, 123, 124, 125, and/or 126, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316, 317, 318, 319, 320, 321 , 322, 323, 324, 325, and/or 326, or

gg3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, or

gg4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 1 15, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 315, or

gg5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 15 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 315 per primer, or gg6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 16 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 316 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 7, or

gg7) which has at least two of features gg1 ), gg2), gg3), gg4), gg5) and gg6); and

a polynucleotide

hh1 ) encoding a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, or a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, or

hh2) encoding a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, and/or 145, or or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328, 329, 330, 331 , 332, 333, 334, 335, 336, 337, and/or 338, or

hh3) which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327, or

hh4) which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 134, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 327, or

hh5) which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or

hh6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

hh7) which has at least two of features hh1 ), hh2), hh3), hh4), hh5) and hh6);

A recombinant polynucleotide as claimed in claim 12 selected from the group of:

aa) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 , or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 243, bb) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 255 or 339, or 339 or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 223,

cc) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, dd) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 279, ee) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291 , ff) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 303 gg) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 15, or a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 315, and

hh) a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 327 . 14. A vector comprising a recombinant polynucleotide of claim 12 or 13.

15. A microorganism comprising a recombinant polynucleotide of claim 12 or 13 or a vector of claim 14. 16. The recombinant microorganism of claim 15, wherin said recombinant microorganism is a bacterium, a fungus or yeast.

17. A process for the production of cornexistin or hydroxycornexistin or the production of cornexistin and hydroxycornexistin comprising the steps of:

b) obtaining produced cornexistin or produced hydroxycornexistin or obtaining

produced cornexistin and hydroxycornexistin.

The process of claim 17, wherein cornexistin or hydroxycornexistin or cornexistin and hydroxycornexistin are obtained from the culture broth.

The process according to any one of claims 17 or 18, wherein at least one of cornexistin or hydroxycornexistin is obtained as dibasic acid thereof or in the form of its agriculturally acceptable salt.

A method to enhance the production of cornexistin or hydroxycornexistin in an cornexistin or hydroxycornexistin producing microorganism comprising the steps of:

I) providing cells of a microorganism capable to produce cornexistin or

hydroxycornexistin,

II) transforming said cells with at least one of a) to h), wherein,

a) is at least one expression cassette encoding

a1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

a5) a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 1 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 243 per primer, or

a7) a polypeptide of at least two of a1 ), a2), a3), a4), a5) and a6);

is at least one expression cassette encoding

b1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

b5) a polypeptide expressed from a polynucleotide which is obtainable via

b7) a polypeptide of at least two of b1 ), b2), b3), b4), b5) and b6);

is at least one expression cassette encoding

c1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

c2) a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, and/or 50, or a polypeptide which is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, and/or 278, or c3) a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 267, or c4) a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 39, or a polypeptide expressed from a polynucleotide which hybridises under medium stringency hybridisation conditions, to a complement of SEQ ID NO: 267, or

c5) a polypeptide expressed from a polynucleotide which is obtainable via

c7) a polypeptide of at least two of c1 ), c2), c3), c4), c5) and c6);

is at least one expression cassette encoding

d1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

d5) a polypeptide expressed from a polynucleotide which is obtainable via

d7) a polypeptide of at least two of d 1 ), d2), d3), d4), d5) and d6);

is at least one expression cassette encoding

e1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

e5) a polypeptide expressed from a polynucleotide which is obtainable via

e7) a polypeptide of at least two of e1), e2), e3), e4), e5) and e6);

is at least one expression cassette encoding

f 1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

f5) a polypeptide expressed from a polynucleotide which is obtainable via

f7) a polypeptide of at least two of f1), f2), f3), f4), f5) and f6);

is at least one expression cassette encoding

g1 ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

g5) a polypeptide expressed from a polynucleotide which is obtainable via

g7) a polypeptide of at least two of g 1 ), g2), g3), g4), g5) and g6);

is at least one expression cassette encoding

hi ) a polypeptide which is at least 80%, 82%, 84%, 86%, 88%, 90%, 91 %,

h5) a polypeptide expressed from a polynucleotide which is obtainable via

PCR on genomic DNA or cDNA of a pamamycin producing organisms using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 134 per primer, or a polypeptide expressed from a polynucleotide which is obtainable via PCR on genomic DNA or cDNA of a cornexistin and/or hydroxycornexistin producing organism using primer pairs of at least 15 consecutive polynucleotides of SEQ ID NO: 327 per primer, or h6) a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or a polypeptide which is at least 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ I D NO: 328 and comprising at least 80%, 90% or all of the amino acids marked with an black arrow in Figure 8, or

h7) a polypeptide of at least two of hi ), h2), h3), h4), h5) and h6); III) identifying transformed microorganism comprising at least one expression

cassette of least one of a) to h) of step II),

21 . The method of claim 20, wherein the microorganism capable to produce cornexistin or hydroxycornexistin is Paecilomyces divaricatus 22. The method of claim 20 or 21 , wherein at least one of cornexistin or

hydroxycornexistin is obtained as dibasic acid thereof or in the form of its agriculturally acceptable salt.

23. Use of at least one of the polynucleotides of claim 12 or 13, or at least one of the

vectors of claim 14, to produce a recombinant microorganism of any one of claims claimsl to 1 1 , 15 or 16.

24. Use of at least one of the polynucleotides of claim 12 or 13, or of at least one of the vectors of claim 14, in a process as claimed in any one of claims 17 to 19 or in a method as claimed in claim 20 or 21 .

Use of at least one of the polynucleotides of claim 12 or 13, or at least one of the vectors of claim 14,, or of at least one of the recombinant microorganisms of any one of claimsl to 1 1 , 15 or 16 for the manufacture of cornexistin or hydroxycornexistin or for the manufacture of cornexistin and hydroxycornexistin.